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Preface
Advances in complex research fields are frequently driven by new
technologies developed within the field, or in a neighboring
field, to which the connections are not immediately obvious.
Drug abuse is a complex problem with significant social,
psychological, and biomedical components, and researchers are
constantly pressed to develop new and better methodologies for
prevention and treatment of drug abuse. The Idea for this review
evolved from a research retreat held 8 years ago, during which
hypotheses on the demand side of the etiology of drug abuse in
general were discussed and specific questions on drug action on
the brain, that might only be effectively studied through the
application of advanced technologies, were first explored. Now
that these advanced technologies are realities and it is possible
to visualize specific neurochemical entities, such as opiate,
dopamine, serotonin, and other receptors, in the living human
brain, the time is ripe for an examination of their potential for
advancing our understanding of the neurobiology of behavioral
control in the drug-abusing population.
This research monograph is a summary of discussions of invited
experts who participated in a 2-day Technical Review meeting held
at the National Institutes of Health campus in Bethesda,
Maryland, on October 3-4, 1985.
Stephen I. Szara, M.D., D.Sc.
Biomedical Branch
Division of Preclinical Research
National Institute on Drug Abuse
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Introduction
Stephen Szara
At a meeting in 1977 of a Task Force on Research on Drug Abuse,
the concept of self-control was identified by many of our expert
consultants as a central issue in drug abuse:
The self-control concept in drug abuse research
should be of high priority, since it integrates a
number of concepts (Joseph Brady).
Looking for commonalities across various substances
of abuse may be an oversimplified notion. The self-
control concept may be the only commonality
(Charles R. Schuster).
Getting rid of drug-using behavior is dependent on
the successful establishment of a substitute
behavior. Drug abuse may be seen as a disorder of
effective self-control (Gene Smith).
Peptides and neurotransmitter amines may affect self-
image, feeling states, or even self-control; we just
have to find ways of measuring It (William Martin).
Some of the consultants actually suggested general guidelines for
research:
The endorphin story is very important and should be
followed up in human studies (Charles P. O'Brien).
To pin down disorders of self-control in drug abuse
patients, we should follow the natural history of
recovery and find out what accounts for their success
(Gene Smith).
Basic research is not necessarily biochemistry,
pharmacology, or anatomy; it is behavior that can
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also be considered basic itself. We need good
objective measures of present status so that we can
measure change (Peter Dews).
Scanning the drug abuse literature for evidence of research
activities on this parameter, I was struck by the relative paucity
of papers in the drug abuse context. Digging into the
psychosocial literature, however, I was impressed with the
numerous studies that focused on the apparently narrow issue of
"locus of control," as measured by a single dimensional scale
devised by Julian Rotter, to assess the external/internal
attitudes for control of life events (Rotter 1966; Rotter 1975).
At least two books (Lefcourt 1976; Perlmutter and Monty 1979) and
hundreds of papers have been published on this topic in various
journals.
Some papers on alcoholism have dealt with subjective feelings of
losing control as a central feature of this disease (Rohsenow and
O'Leary 1978; Abbot 1984), and I found a few papers reporting on
some measure of control as playing a role in other drug abuse
situations (Langrod et al. 1983; Craig 1979).
There have been a number of questions raised in the psychological
literature as to the validity of the Rotter scale of locus of
control, and other psychological variables, such as sensation
seeking, have been suggested as crucial in getting involved with
drugs.
However, a major question can be raised, If self-control is such
an important issue in drug abuse, considering the fact that drugs,
including alcohol, are chemicals acting at the chemical level on
the brain, is there a relationship that can be identified and
explored so that we can gain a better understanding of what is
going on with drugs and the brain? Based on this, could we find
better ways of helping addicts to return to normal life or find
ways to prevent people from becoming addicted in the first place?
There is an enormous gap between the receptors, the points in the
brain where drugs presumably act, and issues at the conceptual
level, such as self-control, sensation seeking, etc. How do we
deal with this gap in a scientific manner? Paul Willner argues
(Willner 1984) that coming to grips with this question is the
central issue of psychopharmacology and proposes at least four
explanatory domains needed to bridge the conceptual gap between
the biochemical and subjective levels:' the biochemical, physio-
logical, cognitive, and subjective. He suggested that we think in
terms of a computer analogy, according to which these four domains
roughly correspond to two levels of hardware and two levels of
software: components and wiring at the hardware level and
programming and editing at the software level. The four levels
may be generally described as follows:
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1. Hardware level.This means the elementary active
operating components, such as transistors, gates, flip
flops, memory registers, etc. in computers. In the
brain these would correspond to neurons, cortical
columns, strfatal patches, islands, etc.
2. Connectivity between the components. In the computer,
connectivity between transistors defines their
interactions and forms the basis for higher level
action. In the brain, the connectivity pattern among
the functional units is extremely complex with multiple
feedback loops forming intricate patterns.
3. Program level. In computers the programs may reside in
a plugged-in module or have to be loaded in by the
user. In animals and humans the situation is much more
complex. Fixed action patterns (FAP) are recognized by
ethologists in animals as genetically determined
programs for action, and some of these are suspected to
have survived the evolutionary process although there
are some doubts as to whether they are operational in
man. In humans, much of the "programning" occurs at the
psychosocial and cultural levels as part of the lifetime
learning process.
4. Editing  level. Here the analogy between brain and
computer breaks down. We don't have an equivalent
feature in computers of fntentfonality, consciousness,
and emotions, just to mention a few of the subjective
phenomena that are of obvious significance for human
behavior.
I would like to avoid getting bogged down in philosophical
discussion of these issues. Rather, I would like to focus on a
relatively narrow aspect of human functioning that would hopefully
be researchable. What I am proposing is to explore the possible
causal relationships between molecular events in the brain, as
revealed by Positron Emission Tomography (PET) scanning, and some
high-level symbolic action, for example holding a specific belief
of locus of control that appears to play a major role in the
decision processes involved in substance abuse.
Bridging the enormous gap that this represents has been attempted
before (Zuckerman 1984). This Technical Review asked the
participants to take a look at the newly emerging potentials of
high technology in visualizing functional states of specific
receptors in the living human brain and explore some concrete
hypotheses relevant to drug abuse that may be resolved using this
technology.
We know from preliminary research that PET-scanning techniques can
visualize receptors in the human brain in vivo (Wagner et al.
1983; Frost et al. 1985). and that locus of control measures are
available and have been useful in assessing some aspects of
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substance abuse behavior (Langrod et al. 1983; Craig 1979).
Animal data suggest that some brain transmitters and/or receptors
are affected by awareness of the availability of "control" (Smith
et al. 1982; Drugan et al. 1981).
The following questions were addressed at the Technical Review:
What kind of specific hypotheses may be formulated that
would be of interest to drug abuse research and that could
be tested using the newly available methodologies?
Are these methodologies sufficiently sensitive and
specific to obtain reliable measures at the
biochemical/receptor level, the clinical/psychological
level, and the behavioral/instrumental level?
What kind of subject population may be most suitable: a
nondrug-using sample from the general population; current
drug users in treatment; some other diagnostic category of
patients; or all of the above?
What would be the most appropriate experimental design
to carry out these studies?
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Basic Research Strategies for
Imaging Neurotransmitter Systems
Solomon H. Snyder
INTRODUCTION
The advent of powerful new imaging techniques, such as positron
emission tomography (PET) scanning and magnetic resonance imaging,
has raised the possibility of evaluating metabolic functions in
the brains of intact humans. Substantial advances have already
been made in PET scanning, especially in studying 2-deoxyglucose
uptake. PET scanning has also been employed to image neurotrans-
mftter receptors such as dopamine, opiate, and benzodiazepfne
receptors. Magnetic resonance imaging has thus far been restrict-
ed to studies of protons, permitting the visualization of anatomi-
cal structures but not studies of metabolism. In the not too
distant future, magnetic resonance imaging is likely to be em-
ployed for phosphorus, so that energy metabolism, such as the
disposition of ATP, will be imaged.
The major limitation of PET scanning is technological. Positron-
emitting isotopes have a very short half-life, so the synthesis of
appropriate ligands must be done at the site of the PET scanning
operation. Additionally, the cost of a cyclotron and the PET
scanning camera equipment is considerable. In some instances, one
might be able to accomplish similar objectives utilizing lfgands
such as iodine-123, which can be detected by single proton emis-
sion tomography, utilizing equipment that is already available in
most academic medical centers.
Thus, at the present time one can image almost any ligand provided
it can be synthesized with the appropriate isotope. For the
information to be useful, the ligand must interact only with the
desf red target site. Thus, if one wished to image opiate recep-
tors, morphine would be unsuitable. While morphine does indeed
bind to opiate receptors, at pharmacologically effective doses
about 80 percent of the morphine in the brain is not bound to opi-
ate receptors, but occurs at adventitious locations. Accordingly,
a sophisticated understanding of the relevant neurochemical system
is necessary to develop appropriate ligands. Sophistication is
also required in determining which systems may be of greatest
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interest for imaging and can be approached with available
technology.
The types of neurochemfcal systems that have been explored or that
may be explored in the future can be placed in several categories.
The first has to do with comprehensive metabolic function as exem-
plified by studies with 2-deoxyglucose. As a neuron fires more
frequently, 2-deoxyglucose consumption increases. It appears that
neurons, rather than glia, account for the bulk of 2-deoxyglucose
uptake. There have been many demonstrations of 2-deoxyglucose
uptake varying with the functional state of neuronal groupings.
Investigators have begun to approach studies of protein synthesis
by PET scanning. As already mentioned, phosphorus disposition
might be evaluated by magnetic resonance.
In this essay, we will not deal with general metabolic markers
for imaging. Instead, we will limit our attention to studies of
neurotransmitter disposition at three levels. One involves label-
ling neurotransmftter receptors. A second involves labellfng
neurotransmitter-specific neurons. Yet a third has to do with
studies of second messenger systems for neurotransmftters.
NEUROTRANSMITTER RECEPTORS
Neurotransmitters come in different varieties, including amines,
amino acids, and peptides. At the present time, well over 50 dis-
tinct neurotransmftter candidates are known, and the total number
may be substantially higher. Generally, there are several sub-
types of receptors for each neurotransmftter. Thus, the multi-
plicity of potential receptors to be imaged is considerable. Why
would one want to image any neurotransmftter receptor? One can
determine the detailed localization of the receptor in animal
studies far more efficiently than in humans. In humans, one pre-
sumably would be Interested prfmarfly in alterations associated
with specific disease states. The second possfbflfty has to do
with changes relating to drug treatment.
What might one be seeking in studies of neurotransmitter receptors
in disease states and following drug admfnfstratian? Presumably,
one would be looking for some sort of alteratlon. Two types of
changes can be potentially detected by fmaging. If the affinfty
of the receptor for its ligand changes, then the amount of a
tracer dose of the lfgand that binds would be altered. For in-
stance, if a given disease state is associated with an alteration
in the protein structures of the receptor, so that its affinity
for ligands is decreased to one-tenth its original affinity, then,
with a tracer dose of radioactive drug, one would probably observe
much less binding. More straightforward would be changes in
actual numbers of receptors. These would be detected with tracer
doses of ligand, as well as with saturatfng doses. Distinguishing
between alterations in affinity or receptor number might be possi-
ble by utilizing different doses of the radioactive ligand in
imaging studies. Changes in receptor number would be apparent by
altered ligand binding of similar magnitude, regardless of the
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dose of radioactive ligand. Altered receptor affinity would be
apparent in terms of changes in ligand binding only with low
ligand concentrations.
Conceivably, certain brain disorders are related to changes in
numbers of receptors. The limited investigations that have been
done thus far in postmortem brain have not been particularly
promising. Thus, though dopamine is thought to be involved in
schizophrenia, any changes in levels of dopamine receptors in
postmortem schizophrenic brain are thought to be related more to
drug treatment than to the disease process (MacKay et al. 1982).
Numbers of various receptors are changed in Huntington's disease
(Penney and Young 1982; Whitehouse et al. 1985), but this is not
surprising considering the vast deterioration of neurons, espe-
cially in the corpus strfatum. The same could be said for reports
of alterations in receptor number in Alzheimer's disease.
Might there be changes in receptor number with varying physio-
logical state? In other words, would extreme and prolonged stress
alter number of receptors? If one anticipates such changes in
receptors to arise from an altered rate of receptor synthesis,
then the likelihood of detecting alterations would depend on the
rate of turnover of the receptors. Receptors are membrane pro-
teins which do not turn over at a very rapid rate. However, rapid
changes in apparent numbers of receptors are associated with con-
formational alterations in the receptor protein; these alterations
change ligand binding. We know that GABA stimulates benzodiaze-
pine receptor binding by allosteric effects that enhance the
affinity of the benzodiazepine receptor for drugs (Olsen 1981).
These types of changes may be the receptor-binding alterations
most likely to correlate with changes in total brain function.
For instance, if a drug-induced change in brain activity led to
increased firing of GABA neurons, the release of GABA might in-
crease the affinity of benzodiazepine receptors, which would be
apparent in augmented levels of ligand binding.
There is yet another way in which transient changes in neuronal
firing might alter apparent numbers of receptors. This has to do
with receptor occupancy by transmitter. The conventional model of
neurotransmitter action assumes that interaction with receptors is
followed by a rapid dissociation of the neurotransmitter, leaving
the receptor vacant for occupancy by the transmitter associated
with the next nerve impulse. On the other hand, there is abundant
evidence that, under some circumstances, transmitters bind with
very high affinity to receptors, so that dissociation is slow.
This is usually the case in receptor desensitization. Many stud-
ies with different neurotransmftters suggest that a major mecha-
nism of desensitization involves tight binding of the transmitter
to its receptor. Also, high-affinity binding of transmitter to
receptor occurs in the "active" state of certain receptors, as has
been best exemplified for catecholamines at beta adrenergic and
dopamine receptors (DeLean et al. 1980; Leff et al. 1985).
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If a transmitter binds tightly to its receptor, then imaging with
a radioactive ligand may indicate an apparent decrease in receptor
number. On the other hand, if one administered a drug that dis-
placed the tightly bound transmitter from its receptor, there
would be an apparent increase in receptor number. Examples of
this phenomenon derive from studies of opiate receptors. In our
earliest investigations of opiate receptor binding following opi-
ate administration, we found apparent increases in receptor number
(Pert et al. 1973). The properties of these increases were quite
similar to increases observed if one merely incubated brain mem-
branes in buffer solutions (Pasternak et al. 1975). In these lat-
ter studies, the increase in receptor binding was associated with
the release into the buffer solution of a small peptide molecule
with affinity for opiate receptors. Accordingly, we suspect that
a certain amount of enkephalin is normally tightly bound to opiate
receptors in a noncovalent fashion. Drug treatment of intact ani-
mals or incubating brain membranes at 37°C releases the bound
enkephalin, increasing the apparent number of opiate receptors.
One might speculate that altered physiological states associated
with increased firing of enkephalin neurons would lead to greater
receptor occupancy of tightly bound enkephalin, with an associated
decrease in apparent number of opiate receptors. Such changes
have been detected in studies wherein rats were forced to swim;
there was an associated apparent decrease in opiate receptor
number (Seeger et al. 1984).
NEURONS CONTAINING SPECIFIC TRANSMITTERS
No well-known disease state is "caused" by demonstrated changes in
receptor number, though we do know of conditions associated with
degeneration of neurotransmitter-specific neurons. In Alzheimer's
disease, there is a relatively selective deterioration of choli-
nergic- and somatostatin-containing neurons. Similarly, in
Parkinson's disease, degeneration of the nigrostriatal dopamine
pathway appears to be responsible for the major symptoms. Imaging
techniques have already been applied to dopamine neurons. 18F-
DOPA is administered to humans; decarboxylation to 18F-dopamine
takes place selectively in dopamine neurons, which can thus be
imaged. This technique has been employed to demonstrate a loss of
dopamine neurons in patients with idiopathic Parkinson's disease
and may detect early stages in the loss of dopamfne neurons, not
yet associated with clinical symptoms of Parkinson's disease. One
cannot predict by any conventional means who will be likely to
develop idiopathic Parkinson's disease, since this condition is
not genetically determined and has no known environmental cause.
MPTP (1-methyl-4-thenyl-1,2,3,6-tetrahydropyridine) is a
Parkinsonism-inducing neurotoxin occurring as a contaminant of
synthetic opiates sold illicitly as designer drugs. Some individ-
uals who self-administered MPTP-containing preparations developed
an abrupt onset of Parkinsonism with demonstration of dopamine
neuronal degeneration at autopsy. However, the great bulk of 500
or more individuals who have received MPTP appear to be devoid of
neurological symptoms. Are any of these individuals at risk to
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develop Parkinsonism? In normal subjects, dopamine neurons
deteriorate with age, so that by the age of 70 most normal people
have only about half of the dopamine neurons they had in young
adulthood. With a loss of 70 to 80 percent of dopamine neurons,
one obtains clinical symptoms of Parkinsonism. Conceivably,
asymptomatic MPTP users have a limited loss of dopamfne neurons,
but, as they grow older, the normal age-related loss of dopamine
neurons would bring them to the threshold where Parkinson's dis-
ease would become apparent. In four MPTP users with no neurologi-
cal symptoms, Calne et al. (1985) have demonstrated a loss of
dopamfne neurons by PET scanning with 18F-DOPA. Presumably, this
or similar techniques could now be employed in patients with very
slight neurological abnormalities suggestive of Parkinson's dis-
ease to provide a differential diagnosis.
How else might one image neurotransmitter-containing neurons?
Conceivably, the precursor strategy might be applicable to other
neuronal populations. For instance, 5-hydroxytryptophan might be
converted to serotonin selectively by serotonin neurons. However,
the enzyme that carries out this transformation is enzymologically
identical to DOPA decarboxylase , so that most of the enzymatic
conversion may take place in dopamine neurons. Choline, the pre-
cursor of acetylcholfne, is involved in many other biochemical
pathways, so it may not be a suitable precursor for the imaging of
acetylcholfne neurons. The same is likely to hold true for glu-
tamic acid, the precursor of GABA. Other amino acid transmitters,
such as glycine or glutamic and aspartic acids, are even more dif-
ficult to approach, because they are involved in so many metabolic
processes.
One approach to labelling transmitter-specific neurons takes
advantage of selective uptake mechanisms. Most amino acids and
amine neurotransmitters are inactivated by reuptake pumps. One
can regard the site where the transmitter is recognized on the
neuronal membrane prior to uptake as an "uptake receptor." Such
uptake receptors have been labelled in biochemical binding studies
for various transmitters. Serotonin uptake sites have been
labelled with antidepressant drugs such as 3H-imipramine, 3H-
paroxetfne, and 3H-citalopram. Uptake receptors for norepineph-
rine neurons have been labelled with the antidepressant 3H-desf-
pramfne (Lee et al. 1982) and the appetite suppressant 3H-mazindol
(Javitch et al. 1984). In binding Studies, dopamine neuronal up-
take sites have been labelled with 3H-matindol, which has similar
affinity for dopamfne and norepinephrine uptake sites. The high-
affinity choline uptake system providing the precursor pool of
choline for acetylcholine synthesis has an uptake receptor that
can be labelled with 3H-hemicholinium, a potent inhibitor of the
high-affinity choline uptake process.
Might it be possible to image these neuronal systems in humans
with lfgands similar to the ones employed in biochemical binding
experiments? The considerations involved in assessing feasibility
are similar to those associated with labelling postsynaptic neuro-
transmitter receptors. Thus, at the tracer concentration of the
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ligand employed, the great majority of the radioactive drug would
have to be associated with the uptake receptor being investigated.
Receptor occupancy is related to the affinity of the ligand for
the binding site. Dopamine and serotonin receptors have been
imaged by PET scanning utilizing derivatives of spiperone with a
dissociation constant of about 10-10M. The opiate that has been
employed for PET imaging 11C-carfentanil, has a similar affinity
for opiate receptors. In intact rats, 3H-diprenorphine, whose
dissociation constant for opiate receptors is approximately
10-10M, occupies 85 percent or more of opiate receptors in the
brain after intravenous-administration. By contrast, 3H-naloxone,
with a KD of about 2x10-9M, occupies only about 30 percent of
receptors under similar conditions. All the drugs that have been
employed as ligands to label uptake receptors have affinities for
uptake sites similar to that of naloxone, or even less affinity.
This would argue against their suitability for imaging purposes.
However, the number of uptake receptors in most cases is substan-
tially greater than the number of postsynaptic neurotransmitter
receptors. Conceivably, a large number of binding sites may make
up for lesser affinity.
SECOND MESSENGERS
In our earlier discussion of neurotransmitter receptors, we were
dealing largely with the recognition site of the receptor. Equal-
ly important are the second messengers, which communicate to the
interior of the cell recognition information. Second messengers
are dynamic and may more likely show changes with varying physio-
logical and pathological states than do the receptor recognition
sites. One might not anticipate major changes in biosynthesis of
second messenger proteins. However, most of the regulation of
second messenger proteins involves allosteric alterations, which
could cause marked and rapid alterations in apparent receptor
number. In vitro biochemical studies suggest this possibility.
What are some of the second messengers that might be explored?
The two major second messenger systems for neurotransmitters are
the cyclic AMP system and the phosphoinositide cycle. The
phosphoinositide cycle has only been recently elucidated but
appears to be involved in conveying messages for numerous neuro-
transmitters including acetylcholine, serotonin, norepinephrine,
and substance P, as well as a variety of hormones and general
mediators such as thrombin and even mitogenic growth factors.
The phosphoinositide cycle involves the triggering by receptor
recognition of the breakdown of phosphatidylinositol-bis-phosphate
into inositol triphosphate (IP-3) and diacylglycerol. IP-3 acts
upon receptor sites on the endoplasmic reticulum to release calci-
um within the cell. Diacylglycerol stimulates protein kinase C by
enhancing its sensitivity to the stimulatory effects of calcium.
The phorbol ester tumor promoters bind with nanomolar affinity to
protein kinase C. Indeed, what was thought first to be the phor-
bol ester receptor appears to be the enzyme kinase C. In this
way, protein kinase C may be regarded as the third messenger in
the phosphoinositide system.
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Protein kinase C can be labelled in binding studies with radio-
active phorbol esters. Autoradiographic maps reveal a discrete
localization of neuronal systems containing protein kinase C
(Worley et al., in press). This presumably provides a map of
those synaptic systems that make use of protein kinase C as a
messenger. Protein kinase C is extremely dynamic. It exists in
soluble and membrane-bound forms. Increases in intracellular cal-
cium trigger a movement of the cytoplasmic enzyme to a membrane-
bound state, which appears to be the active form of the enzyme.
We have found that stressful stimuli, such as needle injections
into the brain or stress associated with the agonal state, cause
ten- to fiftyfold increases in membrane-associated kinase C. The
development of appropriate ligands for imaging protein kinase C
might provide a dynamic reflection of synaptic activity in a num-
ber of neuronal systems. Phorbol esters have high affinity for
protein kinase C, though not as high as that of spiperone for
dopamine and serotonin receptors. On the other hand, the number
of protein kinase C molecules in the brain is more than 100 times
that of serotonin or dopamine receptors, a circumstance that might
facilitate imaging.
The cyclic AMP-forming system possesses a number of components.
Neurotransmitter recognition at receptors triggers an association
of the receptor recognition proteins with ATP-binding protein.
This "G" or "N" protein interacts with the catalytic unit of
adenylate cyclase to cause a conversion of ATP to cyclic AMP.
Some neurotransmitters stimulate cyclic AMP formation while others
inhibit. There appear to be distinct stimulatory and inhibitory G
proteins. Cholera toxin binds with fairly high affinity to the
stimulatory protein, and pertussis toxin binds to the inhibitory
protein. Conceivably, modified forms of cholera and pertussis
toxins might be used for imaging. Of course, these two toxins
would not pass the brain blood barrier without substantial
modification.
Another approach to the adenylate cyclase system might be to image
the catalytic unit of the enzyme, utilizing a derivative of for-
skolin. Forskolin is a plant derivative that potently stimulates
adenylate cyclase. 3H-forskolin binds to the enzyme with nano-
molar affinity. As with protein kinase C, the number of forskolin
binding sites is substantially greater than the number of neuro-
transmitter postsynaptic receptors. Conceivably, some derivative
of forskolin would be useful for imaging the cyclic AMP system.
In summary, the possibility of imaging neurotransmitter-containing
neurons via their uptake sites, postsynaptic receptor recognition
proteins, or second messenger proteins is very real. The limita-
tions at present are not conceptual but merely technological and
within the grasp of presently existing technology. The possibil-
ity of detecting alterations in brain function as a result of
changes in physiological status, drug treatment, or pathology
offers promise for application in the not too distant future.
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Measurement of Neurotransmitter
Receptors by Positron Emission
Tomography: Focus on the
Opiate Receptor
J. James Frost
APPLICATION OF POSITRON EMISSION TOMOGRAPHY TO NEURORECEPTORS
The impetus for developing noninvasive methods to image and quan-
tify neuroreceptors by positron emission tomography (PET) was two-
fold: (1) the recognition that many widely used psychoactive
drugs exert their actions through binding to neuroreceptors, and
(2) the observation that neuroreceptors are altered (in number or
affinity) in some psychiatric and neurodegenerative disorders,
when measured by postmortem methods. For example, haloperidol, a
neuroleptic drug widely used in the treatment of schizophrenia,
exerts its action predominantly by binding to the dopamine recep-
tor and inhibiting dopamfnergic neurotransmission (Creese et al.
1975; Seeman et al. 1975). Postmortem measurements of dopamine
receptors in the caudate nucleus of schizophrenics demonstrate an
increase in the number of dopamine receptors, giving rise to the
hypothesis that schizophrenia is a disorder resulting from an ex-
cess of dopamine receptors (Seeman et al. 1984; Owen et al. 1978).
Development of a method to measure dopamine receptors in vivo
would clearly be useful in confirming or refuting this hypothesis,
as well as providing a basis for rational drug therapy and possi-
ble subclassification of schizophrenia based on dopamine receptor
concentration. Such a method would also have obvious application
to other neuropsychiatric disorders in which receptor number or
affinity is altered.
POSITRON-EMITTING ISOTOPES
Positron emission tomography is a sophisticated method of measur-
ing the distribution of positron-emitting isotopes in the brain or
other body regions (Phelps and Mazziotta 1985; Ter-Pogossian et
al. 1982). The principle of radioactivity detection is based on
the simultaneous detection of two 511-keV gamma rays emitted 180°
apart by a circular ray of opposed detectors. The registration of
only coincident gamma rays by detectors 180° opposed results in
(1) an approved spatial localization of the decaying isotope, and
(2) a simpler correction for gamma ray attenuation when compared
to methods utilizing the detection of single gamma rays. The
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existence of positron-emitting isotopes of several elements of
biological interest makes PET even more suitable for imaging bio-
logical systems. These isotopes include carbon-11 (half-life=20
minutes), oxygen-15 (half-life=2 minutes), nitrogen-13 (half-
life=10 minutes), and fluorine-18 (half-life=110 minutes). When
these isotopes are incorporated into appropriate molecules, bio-
chemical processes that correspond to the labelled molecule can be
measured. Using this principle, it is possible to noninvasively
measure regional cerebral oxygen utilization using 150-02. region-
al cerebral glucose utilization using 18F-fluorodeoxyglucose,
regional cerebral blood flow using 15O-H20, regional cerebral
blood volume using 15O-CO, etc. (Phelps et al. 1979; Reivich et
al. 1979; Phelps et al. 1982; Reivich et al. 1982; Frachowiak et
al. 1980; Mintun et al. 1984b; Grubb et al. 1978; Raichle et al.
1983). When using such methods, the importance of tracer kinetic
models for quantitative estimation of metabolic or other param-
eters cannot be overemphasized; without such mathematical models,
quantitative interpretation of the PET images would not be possi-
ble (Phelps et al. 1982).
RECEPTOR IMAGING
In the case of receptor imaging, the situation is much the same as
described above. One challenge of developing methods for imaging
and quantifying neuroreceptors by PET is in identifying appropri-
ate drugs or ligands to be labelled. Studies carried out over
several years provided the first insights into some of the proper-
ties a compound must have if the distribution of radioactivity in
the brain was to correspond closely to the distribution of a
neuroreceptor following intravenous administration (Klemm et al.
1979; Kuhar et al. 1978; Kuhar et al. 1976; Laduron et al. 1978;
Laduron and Leyson 1977; Hollt et al. 1977; Pert et al. 1975;
Yamamura et al. 1974). For the method to be successful, a high
degree of receptor-specific binding and a low degree of nonspecif-
ic or background binding in the brain had to be achieved at some
time following injection. For the ratio of specific/nonspecific
binding (or total/nonspecific binding) to be high, it became
apparent that drugs with dissociation constants on the order of
1 nM or less were necessary. Under these conditions, ratios of
specific/nonspecific binding as high as 10 could be achieved with-
in a few hours following injection, making the methods amenable to
PET, using positron emitting isotopes with relatively long half-
lives, such as 11C or 18F The higher the ratio of specific/non-
specific binding for a given labelled drug, the more accurately
changes can be distinguished in in vivo receptor binding (other
parameters being constant). This increased accuracy has obvious
implications for the detection and quantitation of neuroreceptor
alterations in disease. A high receptor affinity appears to be an
important property of a ligand if prolonged in vivo receptor bind-
ing is to be achieved, although other parameters may be of impor-
tance (Frost and Wagner 1984).
In some cases, a labelled drug with a high affinity may not be
suitable for in vivo receptor labelling because of the high degree
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of nonspecific or background binding. The nonspecific binding is
difficult to predict prior to in vivo studies, since the relation-
ship between the drug's physiochemical properties and drug distri-
bution, metabolism, excretion, and permeability is complex (Frost
and Wagner 1984). The choice of labelled drugs for PET studies is
therefore currently based on the study of labelled compounds in
animal models by direct tissue dissection methods. To synthesize
labelled drugs is often expensive and laborious, and of question-
able value when their usefulness is in doubt. An improved under-
standing of the relationship between structure and specific- and
nonspecific-binding kinetics could improve the identification of
drugs for labelling neurotransmitter receptors in vivo. This
identification is important since the number of potentially useful
unlabelled drugs far exceeds the number of labelled drugs. Table
1 shows a series of labelled drugs identified for use in PET
studies of neuroreceptors.
TABLE 1. Partial list of drugs labelled with positron-emitting
radionuclides for in vivo neuroreceptor studies
Labelled Drug Neuroreceptor
11C-carfentanil
11C-diprenorphine
18F-acetylcyclofoxy
11C-methylspiperone
18F-methylspiperone
18F-spiperone
75Br, 76Br-bromospiperone
11C-raclopride
11C-SCH-23,390
11C-ketanserin
11C-methylketanserin
11C-methyl bromo LSD
11C-dexetimide
11C-quinuclidyn benzilate
11C-scopolamine
11C-Ro 15-1788
11C-suriclone
opiate
dopamine-2 and serotonin
dopamine-2
dopamine-1
serotonin-2
muscarinic cholinergic
benzodiazepine
OPIATE RECEPTORS
We have utilized 11C-carfentanil, a potent opiate agonist, to
image opiate receptors in vivo in humans (Frost et al. 1985;
Dannals et al. 1985). Carfentanil has a potency approximately
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8,000 times that of morphine in the rat, with a correspondingly
high receptor affinity (Van Daele et al. 1976). Additionally, the
effect of sodium on carfentanil binding is small compared to most
opiate agonists, making carfentanil attractive for in vivo binding
studies (Stahl et al. 1977; Frost and Wagner 1984). The dissocia-
tion constant of carfentanil for mu opiate receptors measured in
the rat brain at 37°C is 0.051 nM (Frost et al. 1985). Carfenta-
nil binds to delta and kappa opiate receptors under similar condi-
tions with a 90- and 250-fold higher dissociation constant.
Therefore, 11C-carfentanil is expected to be highly selective for
mu opiate receptors in vivo.
HUMAN STUDIES
Human studies using 11C-carfentanil were carried out using PET
following the injection of approximately 7 µg (20 mCi) 11C-
carfentanil alone, and following the administration of 1 mg/kg
 naloxone (figure 1). Images obtained immediately following injec-
11C-carfentanil showed homogeneous and approximately equal
binding throughout the grey matter structures of the brain, with
and without naloxone (Frost et al. 1985). When 11C-carfentanil
was administered alone, the radioactivity in structures known to
be rich in opiate receptors such as the thalamus and basal ganglia
increased with time, whereas the radioactivity decreased in the
occipital cortex, a structure with very few opiate receptors
(Kuhar et al. 1973). The ratio of radioactivity when carfentanil
was given alone to that in the presence of naloxone increased
until 30 minutes after injection, then remained relatively con-
stant for up to 60 minutes in the caudate nucleus, thalamus, and
amygdala (data not shown). This value is equivalent to the ratio
of total/nonspecific binding discussed previously. In the amyg-
dala. the ratio of total/nonspecific binding is approximately 7.
This measured ratio is an underestimate of the actual total/non-
specific binding ratio, due to the finite spatial resolution of
the Neuro ECAT PET scanner (Hoffman et al. 1983). When the
corrections in this effect are made, approximately 90 percent of
the radioactivity in the amygdala is estimated to be specifically
bound to receptors. In the caudate nucleus and thalamus, the
percent of specific binding is somewhat less.
Figure 1 shows images from the two 11C-carfentanil studies for the
period 30 to 60 minutes after injection. The three imaging planes
are 32 mm apart with a slice thickness of approximately 16 mm.
The highest radioactivity concentrations are seen in the amygdala,
thalamus, and basal ganglia. Intermediate radioactivity levels
are observed in the frontal, parietal, and temporal cortex, the
cerebellum, and the hippocampus. Low levels of radioactivity are
observed in the occipital cortex, white matter regions, and pri-
mary sensory cortex. This distribution closely corresponds to the
known distribution of human mu opiate receptors (Kuhar et al.
1973).
The images in the bottom row of figure 1 are obtained using 11C-
carfentanil, following pretreatment with 1 mg/kg naloxone. In
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FIGURE 1. Localization of opiate receptors in man using 1 1C-
carfentanil
NOTE: The Images in the top row were obtained using the Neuro ECAT from 30 to 60
minutes after IV administration of 20 mCI 11C-carfentanil, 7 µg. The three
Images were localized using x-ray CT at approximately 7.2, 4, and 0.8 cm
above the canthomeatal Iine. lmages in the bottom row were acquired at the
same time, following IV administration of the opiate antagonist naloxone,
1 mg/kg. and the same dose of 11C-carfentanil used in the first study. The
brightness of each image is normalized for the injected activity, the
acquisition time, and radioactive decay. A preferential accumulation of
activity is seen in areas known to contain high concentrations of opiate
receptors, such as the thalamus, basal gangIia, amygdala. and cerebral Cor-
tex (particularly the cingulate cortex). Conversely, low activity is seen
where opiate receptors exist in low concentrations, such as the occipital
cortex, the postcentral gyrus, and the cerebellum. The Images in the
bottom row demonstrate the low level of nonreceptor binding in the brain.
Binding is not inhibited In the skull or venous sinuses.
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these images, a low and homogeneous concentration of radioactivity
is seen throughout the brain, due to competitive binding of nalox-
one and 11C-carfentanil at opiate receptors. The radioactivity
was not significantly affected in the skin and skull or the venous
sinuses, consistent with the absence of opiate receptors in these
regions.
The ability to measure opiate receptor binding by PET in humans
will permit exploration of questions that cannot be addressed in
animals. Opiate receptors and endogenous opiate peptides have
been implicated in a variety of conditions such as Parkinson's
disease, schizophrenia, depression, pain disorders, and senile
dementia, as well as in individuals predisposed to drug addiction.
BINDING VS. CONCENTRATION
In studying these conditions by PET, opiate receptor binding must
be distinguished from opiate receptor concentration, since opiate
receptor binding can be altered without changing the receptor con-
centration. For example, changes in regional cerebral blood flow,
may alter the quantity of 11C-carfentanil or any other receptor-
blood-brain permeability,tissue composition, or other parameters
binding ligand that is available to bind to opiate receptors, and
thus alter the final image without a change in the number of opi-
ate receptors. Additionally, changes in the rate (e.g., a KD
change) may also alter opiate receptor binding. Therefore, until
nonreceptor parameters are taken into account, changes in radio-
activity levels from any receptor-binding ligand must be viewed
cautiously when studying neurological and psychiatric disorders.
TRACER KINETIC MODELING
Tracer kinetic modelling can permit the unravelling of a complex
process in vivo, so that the number of binding sites or rate
constants can be estimated if parameters such as the arterial
concentration of the tracer, regional cerebral blood flow, region-
al cerebral blood volume, and other parameters are known (Phelps
et al. 1982; Mintun et al. 1984b). Using such approaches, it has
been possible to determine quantitative estimates of important
biological processes such as regional cerebral blood flow, region-
al cerebral glucose utilization, and regional cerebral oxygen
utilization. Similar methods can also, in principle, be applied
to receptor binding in vivo as measured by PET.
A primary piece of independent information, which is necessary to
apply such techniques, is the tracer concentration as a function
of time in the arterial plasma. Most, if not all, of the labelled
drugs that have been used for receptor imaging are metabolized in
vivo. For example, we have measured the metabolism of 11C-carfen-
tanil in human plasma during PET scan studies. At 10, 30, and 60
minutes after injection, the fraction of the total plasma radio-
activity represented by 11C-carfentanil is approximately 85, 45,
and 25 percent, respectively. In addition, greater metabolism of
11C-carfentanil was observed following pretreatment with 1 mg/kg
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naloxone. Using this information, the true kinetics of 11C-
carfentanil in the plasma can be computed and used with tracer
kinetic models. Additional issues to be addressed are the ability
of metabolites to enter the brain and the receptor-binding poten-
tial of metabolites. Although metabolites can be measured direct-
ly using chromatographic methods, the process is laborious and not
easily translatable to routine clinical studies. Following a
rigorous approach to tracer kinetic modelling, with the accurate
estimation of all involved rate processes, it should become
possible to simplify the methods where appropriate.
AREAS OF INVESTIGATION
In studying opiate receptor binding or binding to other receptor
types in vivo by PET, three fundamental areas of investigation can
be identified. First, it is of great interest to identify and
characterize changes in receptors as a function of disease and
aging. In this respect, it is of interest to obtain quantitative
estimates of receptor concentration and the rate constants for
receptor binding, which then can be compared to values obtained in
normal populations. This approach may lead to an improved bio-
chemical characterization of neurological and psychiatric disor-
ders, an ability to identify disease subtypes, and a rational
approach to drug therapy.
Second, in some receptor systems, it may be possible to detect
changes in receptor binding following alterations in receptor
occupancy by endogenous neurotransmitters. For example, it has
been recently demonstrated that the stress of swimming reduces
apparent opiate receptor binding in vivo, presumably by releasing
enkephalin, which then occupies receptors (Seeger et al. 1984).
Using this approach, the physiologic role of the opiate system
could be elucidated by PET scanning, usfng control-test paradigms
following stressful or painful stimuli. This approach could also
be used to study opiate addiction and withdrawal.
Third, changes in opiate receptor occupancy following the adminis-
tration of exogenous drugs can also be detected, as was demon-
strated for naloxone in the case of opiate receptor binding. Drug
therapy is currently monitored when possible by following the
plasma drug level, although, in many cases, the plasma level does
not closely mirror the therapeutic response. Ideally, the effec-
tive concentration of the drug at the receptor site with which it
interacts would be monitored. For example, it has been demon-
strated by PET that approximately 85 to 90 percent of dopamine-2
receptors in the putamen of schizophrenic patients are occupied by
conventionally used antipsychotic doses of neuroleptic drugs
(Farde et al. 1986). Similar studies are in progress using 11C-
carfentanil to assess changes in opiate receptor occupancy and the
correlation of those changes with behavioral and subjective
changes in chronic-pain patients receiving morphine and related
drugs, narcotic addicts, and former addicts receiving methadone or
naltrexone.
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SUMMARY
In summary, it is now possible to image the distribution of sev-
eral neurotransmitter receptors by PET. When quantitative esti-
mates of receptor number and affinity can be made, it will be
important to study (1) changes in receptor number or affinity as a
function of disease, (2) changes in receptor occupancy by endoge-
nous neurotransmitters, and (3) changes in receptor occupancy and
correlation with behavior during drug treatment.
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The Personality Structure of
Heroin Addicts
Robert J. Craig
INTRODUCTION
When a search of the literature for data that other clinicians and
researchers found in the area of personality characteristics of
drug abusers failed to uncover such a body of material, I decided
to produce it myself. My investigation culminated in several
research reviews (Craig 1979a; Craig 1979b; Craig 1982a; Craig
1982b).
My first review uncovered 98 articles from 1925 to 1975, and my
second review found an additional 47 articles from 1976 to 1979.
Clearly, research in this area was burgeoning with interest. This
is even more noteworthy when you understand that I included in
these reviews only articles that were empirical and that adminis-
tered some type of assessment instrument. Clinical articles and
those based on opinion were not included in my review.
Given the steady volume of papers published on the personality
characteristics of drug addicts since then, another review was
warranted. (Within the last 5 years, another 50 papers have
appeared in scientific journals.) I wanted to produce more of an
integration and knowledge summary than my earlier work; when my
task was finished, I had produced a 75-page paper (Craig 1985b).
When Dr. Szara from NIDA said he wanted someone to discuss what is
known about the personality characteristics of drug addicts, in my
hand was the very paper I needed.
What follows is a distillation of this 75-page effort, adjusted
for the needs of this technical review.
METHODOLOGY
The methodology for this paper was simple but tedious. A litera-
ture search was conducted for any empirical study that used a
psychological test or scale with heroin addicts (HAS). Among
heroin addicts we include clients who abused any opiates, such as
heroin, methadone, codeine, Talwin, etc., but the overwhelming
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emphasis in the literature has been on street addicts who abuse
heroin. The reasons for limiting this search to HAS are:
Opiates constitute the primary drugs of abuse in most drug
treatment programs, so these findings would have a significant
relevance to most of the drug abuse programs in the nation;
The literature overwhelmingly focuses on characteristics of
opiate addicts, perhaps because of their availability in drug
treatment programs and prisons.
Other than marijuana studies, there is a relative paucity of
research on personality characteristics of addicts who abuse
other drugs besides heroin, except when these abusers are
contrasted with a heroin-using group, so these studies are
likely to appear in this review as well.
While marijuana studies are plentiful, they often rely on
college students, and a primary marijuana-abusing client is a
rarity in most drug treatment programs.
ASSESSMENT INSTRUMENTS
By looking at the assessment instruments used in this research, we
can determine the areas of personality functioning that have
captivated the interest of researchers. The following is a rank
order of the most frequently used personality tests and scales
that appeared in this literature: the Minnesota Multiphasic
Personality Inventory (MMPI), the Eysenck Personality
Questionnaire/Maudsley Personality Inventory, Rotter's Locus of
Control Scale, Zuckerman's Sensation Seeking Scale, the Beck
Depression Inventory, the Adjective Check Lists, the Tennessee
Self Concept Scale, Rorschach, the Addiction Severity Index, the
16 Personality Factor Questionnaire, and Figure Drawings. We can
infer from these measures that investigators have focused largely
on such areas as general personality traits and symptoms, intro-
version/extraversion, locus of control, sensation seeking, depres-
sion, psychological need structure, self-concept, and something
akin to unconscious conflicts.
COMMENT ON METHODOLOGICAL ADEQUACY OF THE LITERATURE
Barnes (1979) has made a useful distinction between the preclini-
cal personality (those traits and behaviors exhibited prior to the
onset of addiction) and the clinical personality (how the patient
presents following the onset of addiction) of the drug abuser.
All the research cited here pertains to the clinical personality
of the drug addict. We have no studies whatsoever that have
tested people prior to the development of their addiction. HOW-
ever, we are not arguing that these traits did or did not predate
addiction. We merely suggest how a typical drug addict tends to
appear on psychological tests and what areas show improvement with
treatment. We find the concept of the "addictive personality" not
useful, clinically or otherwise, whereas a description of the
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clinical state of the addict, including his personality, is cen-
tral to the assessment process itself.
Most of the research is based on samples of males. Only recently
has literature appeared dealing with the personality traits of
female addicts.
The methodological adequacy of some of the studies varies, espe-
cially in determining an adequate control group with which to
compare addicts. For a more in-depth understanding of this issue,
the reader is referred to articles addressing this problem (Craig
1979b; Nathan and Lansky 1978).
PERSONALITY CHARACTERISTICS OF HEROIN ADDICTS
Locus of Control
Since locus of control is a major content item at this conference,
I want to make sure that I cover the studies that have used this
as a measure to study HAS.
Locus of control measures the extent to which a person perceives
gratification and rewards as emanating from personal actions and
responsibility (internal locus of control), or whether they are
perceived as emanating from luck, fate, chance, or the assistance
of others (external locus of control). An internal locus of con-
trol is more often associated with good psychological adjustment,
while an external locus of control is linked to maladjustment and
psychopathology.
Probably, after hearing this definition, one would predict that
HAS have an external locus of control orientation, but there are
conflicting findings in the literature.
Seven studies have found HAS to have an internal locus of control.
For example, Berger and Koocher (1972) found an internal locus of
control, plus a significant drop in externality, following an
announcement that a treatment facility would close. Here the
addicts were not depending on luck, fate, or help from others to
find alternatives. This suggests that locus of control can be
subject to environmental fluctuations as well as being a general-
ized trait. No evidence was reported to show that directionality
was maintained over time. These results may simply reflect the
addict's need and resourcefulness at locating another source of
supply.
Berzins and Ross (1973) found that black addicts were more exter-
nal than white addicts, female addicts of both races were more
external than males of both races, and black female addicts were
more external than other comparison groups. However, 85 percent
of the total sample of 1,400 had an internal locus of control.
Callichia (1974) found HAS on methadone maintenance to be more
internal than abstinent addicts. It would have been interesting
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to note whether or not any changes in control orientation occurred
after placement on methadone maintenance, but this study design
did not permit such a finding.
Studies using a trait approach to locus of control have demon-
strated that addicts become more internal after 18 months in a
therapeutic community (De Leon et al. 1973) and after 9 weeks on
methadone maintenance (Henick and Domino 1974).
Two other studies (Smithyman et al. 1974; Platt and Scurra 1974)
also found HAS to have an internal orientation.
Now for the apparent conflict: Five studies have found addicts to
have an external locus of control (De Leon et al. 1973; Obitz et
al. 1973; Obitz et al. 1974; Manganello 1978; Pearlstein 1980).
The Pearlstein study compared locus of control in 38 HAS, 34 alco-
holics, and 21 amphetamine users. The amphetamine group were more
externally directed than the HAS and the alcoholics.
Two studies found HAS to be undifferentiated in directionality
(Langrod et al. 1983; Platt 1975).
Methodology seems to account for these differences. In almost
every case where no control group was used and where addict scores
were compared to published norms of college students, HAS were
found to be externally directed. In studies which used relevant
control groups, results generally showed HAS to be internally
directed.
There are two issues that I want to address now. First, does it
make any difference whether addicts are internal or external in
orientation, and, second, how can drug addicts be internal anyway?
As to the first issue, locus of control as an orientation is
irrelevant unless it can be shown to be related to something else
more important. For example, in the Langrod et al. study (1983),
the hypothesis was tested that methadone maintenance patients with
an internal locus of control would be more likely to be willing to
begin detoxification. Results showed a "nonsignificant trend" in
support of that hypothesis. To a statistician, a nonsignificant
trend is no trend at all, and the null hypothesis is accepted.
Thus, having an internal locus of control was not much different
from having an external locus of control, when it came to begin-
ning methadone detoxification. A more promising lead seems to be
in the area of "detoxification phobia" (Milby et al. 1980). I am
involved with a project now with Dr. Milby at the Veterans
Administration Medical Center in Birmingham. We believe that many
patients have developed a clinical phobia about methadone detox,
and plan to test this idea in a multicenter project. I suspect
that this will bear more fruit than considering their locus of
control.
Second, Strassberg and Robinson (1974) found that addicts with an
internal locus of control had higher levels of self-esteem, better
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psychological adjustment, and higher motivation to achieve
success, and that locus of control orientation was not correlated
with length of drug use.
The idea of a HA having an internal locus of control, as indicated
by the literature, seems paradoxical. I suspect that they are
"pseudointernals." It is quite possible that the internal locus
of control seen in addict self-reports is largely a cognitive and
intellectual self-report that does not match day-to-day behavior.
It seems to serve a defensive function and to reinforce group
norms that assert that they are in charge of their lives. How-
ever, I suspect that HAS do not behave as if they were internal.
At the risk of getting "soft," let me cite some clinical material
that seems consistent with my view.
Wellisch et al. (1970) have reported on a relationship dyad among
HAS where the male member is supported and taken care of by the
female member, who typically adopts the role of pseudomother for
her male partner; hence the term "easy rider" syndrome. Out-
wardly, the male appears to be along for the joy ride and looks
independent. Inwardly, he is passive-aggressive in the fullest
sense, extremely dependent on someone to guide him through life.
When the relationship ends, he finds someone else to play this
role in his life.
Ganger and Shugart (1966) further report that the aggressive
behavior that some addicts exhibit toward their families when high
is actually "pseudoassertive" behavior that plays an important
role in family dynamics and that results in keeping the addict
addicted and dependent.
What is actually seen in these two examples is behavior that is
very externally oriented under the appearance of an internal
orientation.
Sensation Seeking
Sensation seeking as a trait, suggested as a possible factor in
the onset of heroin use, explores the tendency of addicts to
engage in thrill, adventure, and altered states of consciousness.
Most studies indicate that drug addicts have higher scores in
sensation seeking than normals (Galigio and Stein 1983; Platt
1975). This seems to hold true for drug use in college students
(Zuckerman et al. 1972) and for addicts on methadone maintenance.
Sensation seeking traits probably predated their involvement with
opiates (Kohn et al. 1979). Drug addicts seem to show a prefer-
ence level of stimulation in sensation-seeking experiences that is
not seen among nonusers (Reith et al. 1975). Sensation-seeking
scores have been related to hallucinogen use in members of a labor
union (Khavari et al. 1977) and to the frequency of hallucinogen
use among Hispanic males in residential treatment (Kaestner et al.
1977). They also have been positively related to stimulant and
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hallucinogen use and negatively related to the use of depressants
(Carol and Zuckerman 1977; Galigio and Stein 1983).
White addicts show higher levels of sensation seeking than black
addicts (Kaestner et al. 1977; Sutker et al. 1978). Addicts who
were higher in sensation seeking also used more categories of
drugs, had an earlier age of onset of first drug use, and cited
curiosity as their initial motive for using drugs.
Female addicts did not differ from male addicts in sensation
seeking (Sutker et al. 1978), and no differences occurred among
groups with high rates of parole success compared to recidivists
(Platt and Scurra 1974) on sensation-seeking traits. Successful
treatment in a therapeutic community decreased sensation-seeking
traits among addicts, but no comparable reduction was observed for
addicts in prison (Skolnick and Zuckerman 1979).
I would like to make one last point. Eyre et al. (1982) found
that 22 percent of a population of 157 HAS reported childhood his-
tories of hyperactivity. Craig (1984a) reported that, based on
almost 500 MMPI profiles, HAS typically have high Scale 9
(hypomania) scores. All this seems to correlate with some central
nervous system "something." I would like to see a group of HAS
with high sensation-seeking scores and high Scale 9 scores in
studies designed to address the following questions: Do they have
histories of hyperactivity? Are their EEGs abnormal? What would
the results of CAT/PET scans show, when equated with HAS without
high sensation seeking and high hypomania scores?
SUMMARY OF PSYCHOLOGICAL TEST ASSESSMENTS
What follows is a summary of my 75-page review. You will have to
trust that what I am now reporting is true, since few references.
other than my own summary (Craig 1985b), will be presented:
Opiate addicts, as a group, score in the average range of IQ
level; this finding is true among a variety of addict subgroups
and is independent of the type of intelligence test used to
make the assessment.
Addicts show no group differences in development of moral
values and function largely around Kohlberg's Stage 3
(preconventional) level of moral reasoning. Any deficiencies
observed in this area by addicts are due to defective ego
controls rather than to deficits in moral reasoning.
Addicts tend to score in the mild to moderate range of
depression on most psychological tests and rating scales.
These depression scores subside with treatment.
Drug addicts are undifferentiated with respect to the traits of
introversion/extraversion.
30
Most addicts score in the direction of internality on locus of
control orientation, as opposed to alcoholics who score as
externally oriented. However, this is misleading and merely
reflects a cognitive belief which addicts hold as a defense--a
belief that is not matched by their behavior. Locus of control
is also subject to temporary fluctuations based on environ-
mental threats. Addicts' locus of control moves toward greater
internality following appropriate treatment.
Psychiatric studies show that drug addicts have a paucity of
major psychiatric syndromes and neuroses and a plethora of
personality disorders and character disorders. Psychological
tests confirm this finding. This is not to say that major
psychiatric syndromes cannot coexist with drug addiction, but
merely that such a condition is the exception.
All studies found that addicts have a poor self-concept, which
improves with certain types of treatment.
Addicts have a higher need for sensation seeking than normal
controls.
Addicts are field dependent, relying on their environment to
give them structure and support.
Studies testing addicts' need hierarchies have often found them
to be high in self-reported dominance, aggression, succorance
(dependence), change, heterosexuality, and autonomy, and low in
endurance, affiliation, and nurturance. They report themselves
to be high in need for achievement, but their daily behavior
does not match this report. On most tests, addicts would be
described as hostile, demanding, aggressive, rebellious,
irresponsible, playful, impulsive, and independent, making the
establishment of a treatment alliance quite difficult.
Opiate abuse results in little or no impairment in cerebral
functioning (except for acute effects), as measured by neuro-
psychological tests given up to 9 weeks following abstinence.
When differences have been found, they have been described as
mild and detectable only with specialized tests, but not
suspected clinically.
A number of variables can influence test findings, particularly
time of testing, ethnicity, class of drugs, reasons for seeking
treatment, and the presence of coexisting clinical syndromes.
If the goal is to detect substance abuse with psychological
tests, then the MacAndrew Alcoholism Scale of the MMPI is
currently the best psychologically based scale to provide
information about substance-abusing tendencies.
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PERSONALITY STRUCTURE OF HEROIN ADDICTS
Research using psychological tests and scales has found the per-
sonality of drug addicts to have the components of a weak ego,
character-disordered traits, field dependence, and stfmulus
augmentation. These findings parallel, but are somewhat different
from, similar reports on the alcoholic personality (Barnes 1979).
Weak Ego
Addicts, like alcoholics, have a weak ego, but it is manifested
somewhat differently from the personality of alcoholics. Like
alcoholics, they have a negative self-concept, show hostility,
immaturity, and impulsiveness , and have a low tolerance for
frustration. They are oriented toward the present rather than
showing goal-oriented behavior toward the future. Unlike alco-
holics, they have a strong sexual identity, with high need for
heterosexuality but low need for endurance and affiliation. This
suggests that addict sexuality may be another area in life where
other people (females) are used to gratify and satisfy the
addict's need for intimacy without reciprocity or need for lasting
attachments.
Character-Disordered Traits
Addicts have traits typical of traditional antisocial psychopathy.
Relationships are superficial and instrumental only to the extent
that others gratify their narcissistic demands. Depression is
mild but chronic and low level. Anxiety is manifested through
impulsive behavior and somatic defenses. They aggress to achieve
their ends, try to dominate relationships, and are poor treatment
risks.
Field Dependence
Addicts are more field dependent than normals, suggesting that
they have a higher need for dependency than do normals. They rely
on their environment to provide them with structure and support.
Stimulus Augmentation
Addicts cannot tolerate boredom, are playful, want change, are
exhibitionistic, high in sensation seeking, and are stimulus
augmenters rather than stimulus reducers.
IMPLICATIONS FOR FUTURE RESEARCH
Now that the personality structure of heroin addicts is somewhat
in hand, the question remains, "So what?" Where do we go from
here?
I think we are at a point in our knowledge where it is no longer
sufficient merely to give drug addicts a personality test and then
report the results (the one exception might be cocaine abusers,
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for whom little information other than demographics presently
exists). I believe that future directions should relate person-
ality traits and styles to other variables of interest, particu-
larly treatment response and treatment outcome (Craig 1982b).
This is the direction my own work has taken. For example, we have
learned that personality traits, as measured by the MMPI and the
Millon Clinical Multiaxial Inventory, are not related to treatment
dropout in our program (Craig 1984b; Craig 1984c), whereas inter-
actional concepts have proved to be quite reliable indicators of
dropout upon cross-validation (Craig et al. 1982). Relating
personality traits to other variables of interest is the direction
in which we have to go.
Another important area has to do with effectiveness of treatment,
particularly personality change as a result of treatment. Most
drug addicts are treated in programs and not in private practice
(Craig 1985b). In our own program, we have data that demonstrate
the effectiveness of methadone maintenance (Craig 1980) but no
data on the effectiveness of our inpatient unit. We are currently
using the Adjective Check List, measuring needs, to see if need
patterns change after 3 weeks of intensive rehabilitation.
Retrospective studies are needed to determine the personality of
drug addicts prior to addiction. A few seminal reports of this
kind are available in the alcoholic literature and would be
extremely enlightening in the drug abuse literature as well. If
NIDA wants to have a real effect in this area, it should create a
grant for a researcher to go into a community, select random sam-
ples of community residents at risk for and with equal access to
drugs, and then follow them over time. The researcher should find
out which ones become addicts and which ones do not, then go over
their psychological test data to see if any traits or scores dis-
tinguish the users from the abstainers. This is what is really
needed.
We know quite a lot about how drug addicts appear on psychological
tests; now we have to determine what this means.
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Locus of Control and Need for
Control Among Heroin Users
Don C. Des Jarlais
INTRODUCTION
“LOSS of control" over substance use has long been considered to
be one of the primary characteristics that distinguish the true
"alcoholic" or "addict" from the "heavy user." The standard
conceptualization of full loss of control involves both use to the
point at which there are severe negative consequences of substance
use for the individual and an inability ever to return to "moder-
ate" levels of use. The purpose of this monograph is to examine
possible new research techniques for interdisciplinary study of
this central problem in substance abuse. As part of this purpose,
we will first review some of our previous research on locus of
control among heroin users and then report on our current studies
of control over drug use among heroin users.
The concept of locus of control was first developed by Rotter
(1966) and was defined in terms of the individual's perception of
control over his or her reinforcements. A person with an
"internal" locus of control believed that control over reinforce-
ments resided primarily within the individual; thus, rewards were
mainly the result of efforts and deliberate choices. Persons with
an "external" locus of control believed that control over re-
inforcements was located outside the individual. and that rewards
were primarily determined by factors such as fate, chance, or
powerful others.
There is a great volume of research on locus of control in the
psychological literature, with the great majority of findings
linking internality with positive mental health (Lefcourt 1976).
Since drugs are readily identifiable and powerful reinforcers,
there was an expectation that strong relationships between locus
of control and drug use might be found. Unfortunately, there are
contradictory findings as to whether drug users are internal
(Berzins and Ross 1973; Carroll, unpublished dissertation; Gross
and Morosko 1970) or external (Palmer 1971; Obitz et al. 1973),
and, if they are internal, whether they are "true" internals
(Berzins and Ross 1973; Carroll, unpublished dissertation) or
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"pseudo" internals (Lefcourt 1976). Craig (this volume) recently
reviewed studies of locus of control among substance abusers and
found approximately equal numbers of studies showing drug abusers
to be internal, external, and neither internal nor external.
PRIOR STUDY
Several years ago, we conducted a study of locus of control among
methadone maintenance patients in an attempt to clarify relation-
ships between locus of control and drug use. We believed that
clarification might be achieved by studying a specific behavior--
voluntary detoxification from methadone maintenance--that had
clear implications for control (Langrod et al. 1983).
Voluntary detoxification was selected as a specific behavior
because of its many links to control in patients' lives. Success-
ful voluntary detoxification would objectively increase patients'
control over their lives. Patients would no longer have to report
to a clinic one or more times per week, receive mandatory counsel-
ing, submit urine specimens for analysis, or obtain prior approval
for personal or business travel. Voluntary detoxification is also
seen by patients as a desired treatment goal that depends upon
willpower and effort rather than chance factors.
From the great number of studies that showed relationships
between internality and positive mental health, we generated two
hypotheses:
Internality would be positively associated with stated willing-
ness to begin a voluntary detoxification.
Internality would be positively associated with actually begin-
ning a voluntary detoxification within the 90-day followup
period. (A reduction in methadone dosage was required as
evidence of actually beginning detoxification.)
These hypotheses were tested in a sample of 115 male methadone
maintenance patients, who were given the Rotter Locus of Control
Scale, interviewed regarding their perceptions of and willingness
to begin a voluntary detoxification, and then followed to see
which subjects had actually begun such a detoxification.
The findings from this study did not resolve ambiguities in the
relationships between locus of control and drug use. First, the
mean score on the Locus of Control Scale was 8.9, which was
neither "internal" nor "external" when compared to the means from
a large number of other samples. Second, there was only weak
support for the first hypothesis , a correlation of 0.15, p<.11,
between internality and stated willingness to begin detoxifica-
tion. Finally, there was a reversal of the second hypothesis.
Among those subjects who indicated a willingness to begin detox-
ification, there was a statistically significant negative corre-
lation between actually beginning detoxification (r=-0.30 with
Locus of Control Scale, p<.012) and internality,
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REFORMULATION: NEED FOR CONTROL AS A MOTIVE FOR BEHAVIOR
These findings led us to question the value of the concept of
locus of control in studying drug use and abuse. Locus of control
is conceptualized as a relatively stable personality trait, a be-
lief about how the world works and the person's relationship to
the working of the world. Our findings were best interpreted in
terms of a varying need for control. Need for control would vary
with both the general life situation of the individual and the
specific immediate situation. In general (outside of pathologic
conditions), control over reinforcers would be valued. Individ-
uals who experience a sense of control over their reinforcers will
defend against losing their sense of control, and individuals who
experience a lack of control over reinforcers will actively seek
means of reestablishing such control.
By definition, drugs are an important set of reinforcers for “drug
abusers," and "control" over drug use thus will be an important
part of their lives. The methadone patients who felt a lack of
control over reinforcers (the "externals") would thus begin detox-
ification to gain a sense of control. Those methadone patients
who experienced a sense of control over reinforcers (the "inter-
nals") would avoid actually beginning detoxification, since fail-
ure at this important task would be a clear threat to their sense
of control. (The likelihood of successful detoxification and
abstinence afterward is relatively low, approximately one in six
(Des Jarlais et al. 1981)).
Within this reformulation, the Locus of Control Scale can be used
as an imperfect measure of need for control. "Externals" would be
considered to have an unmet need for control and would be likely
to take action that would lead to an increased degree of control
over reinforcers. "Internals" would be considered to have their
need for control met and would avoid action that would threaten
their current sense of control. The scale is thus being used to
measure differences in situationally produced motives for
behavior, not differences in the personalities of individuals.
This reformulation is consistent with the one area in which there
are theoretically plausible and empirically consistent data re-
garding locus of control and drug abuse. Studies from therapeutic
community treatment (De Leon et al. 1973) and methadone mainte-
nance treatment (Henik and Domino 1974) show change from external-
ity to internality during time spent in drug abuse treatment. An
unmet need for control over reinforcers would lead individuals to
enter treatment, and successful adaptation to treatment would be
associated with developing a sense of control over reinforcers in
one's life.
PILOT STUDY OF INTRANASAL HEROIN USERS
We have since conducted another study of methadone patients, rele-
vant to relationships between perceived need for control and
important drug use behavior.
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Acquired immunodeficiency syndrome (AIDS) has become the major
health threat to intravenous (IV) drug users in New York City.
Over 1,500 IV drug users in the city have contracted AIDS as of
September 1985; the total number of cases continues to double
approximately every year (New York City Department of Health
1985). HTLV-III/LAV, the virus that causes AIDS, appears to be
spread through the sharing of "works" (needles and syringes) among
IV drug users (Cohen et al. 1985; Weiss et al. 1985). As part of
our ongoing research on AIDS among IV drug users, we conducted a
pilot study of persons who had used heroin intranasally (sniffed)
to the point where they required methadone maintenance treatment,
but who had not become regular drug injectors.
Injecting heroin is a much more physiologically efficient route of
administration. (Our subjects estimated that they had to purchase
approximately three times the amount of heroin for sniffing to
achieve the same effects as by injecting.) Persons who sniff
large amounts of heroin are important to study, both in relation
to the practical aspects of limiting the spread of HTLV-III/LAV
among drug users and in relation to the theoretical issues of
control over amount of drug use and route of administration.
We interviewed 16 subjects with histories of intranasal use of
heroin who had entered a New York City methadone maintenance pro-
gram during the previous year. These represented the majority of
20 such persons who had been treated at this particular program
over the previous 18 months.
The subjects were relatively young (mean age of 21 years, range of
17 to 24), primarily Hispanic (87.5 percent Hispanic, 12.5 percent
non-Hispanic white) and female (62.5 percent). They reported a
range of 2 to 9 years of sniffing heroin prior to entry into
treatment (mean of 4 years). They had used a variety of other
drugs, primarily marijuana and cocaine (not injected), in addition
to heroin. Of the 16, 4 had injected heroin but had not continued
this route of administration. They reported using an average of
$40 per day of heroin (four $10 bags) prior to entry into treat-
ment (range from 1 to 10 bags).
The two questions in the interview that were most relevant to the
sense of and need for control were the reasons for not injecting
heroin and the reasons for entering treatment. (These questions
were open-ended and were asked prior to any questions on AIDS, to
reduce any interview demand characteristics. The respondents
could give multiple reasons but were not prompted with respect to
any particular reason.)
For the question concerning why the subject did not inject drugs,
14 of the 16 respondents mentioned a fear of needles. This fear
was often described as originating in childhood experiences with
physicians and involved both fear of pain and anxiety/nausea at
the thought of bleeding.
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The second most frequently given response to the question on not
injecting heroin, mentioned by 11 subjects, was the belief that
injecting would lead to becoming a "street junkie." A street
junkie was described as a person for whom heroin use completely
dominated all other activities. For the junkie, all other values,
commitments, and relationships were sacrificed to obtaining and
using heroin. This sacrificing of all other interests was seen as
the final stage in loss of control over heroin use.
Significantly, this stage of loss of control also was seen to
involve loss of self-esteem and social respect. In talking about
street junkies, subjects made statements such as, "I didn't want
to get that low,"and "I couldn't see myself doing that." Respect
from others would be lost because being a junkie could not be
concealed from others.
("tracks,"
Both the physical evidence of needle use
the scars from frequent injection) and the willingness
to "do anything to obtain drugs" (including stealing from friends
and relatives, committing serious crimes on a frequent basis)
would lead others to learn of one's condition.
Interestingly, none of the subjects specifically mentioned a fear
of AIDS as a reason for not injecting drugs, though later in the
interview the majority did express great concern about AIDS.
Relationships among knowledge of AIDS, personal experience with
AIDS victims, and the decision not to inject drugs will be
presented in a separate paper.
The majority of reasons given for entering treatment were phrased
in terms of control over heroin use. Nine of the respondents
stated that they could no longer manage their use of heroin.
Physical dependence had developed, efforts to limit use had
failed, and they were now devoting large resources to heroin con-
sumption (an average of $40 per day). This situation was often
described in terms of "being tired" of the "hassles" involved in
obtaining large quantities of heroin.
The second most frequently cited reason for entering treatment was
to avoid consequences of heroin use that were foreseen but had not
yet occurred. Seven respondents stated that they had entered
treatment to avoid impending negative consequences; of these,
three wanted to avoid becoming "street junkies," and two wished to
avoid becoming bad mothers to their children.
DISCUSSION
The results of the pilot study readily fit with the need-for-
control formulation derived from the methadone maintenance detox-
ification study. Results indicate that individuals will defend
against loss of control over their reinforcers, and if loss of
control should occur, will actively seek to reestablish control.
Avoiding injection was often described as avoiding a fundamental
loss of control. Seeking treatment was typically described as an
attempt to regain control.
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The pilot study results have conflicting implications for the idea
that drug abusers are characterized by either an internal or an
external locus of control. The pretreatment loss of control over
heroin use would be an experience that should induce an external
locus of control, while the ability to avoid regular injection of
heroin would be an experience consistent with an internal locus of
control. Thus, one can generate plausible predictions for either
"internality" or "externality" among these intranasal heroin
users. Locus of control scores taken at the time of the inter-
views (after treatment had begun) would not help in resolving
these contradictory implications, given the previously cited
studies showing movement towards internality with time in
treatment.
CONCLUSIONS AND IMPLICATIONS FOR FUTURE RESEARCH
From present data, there seems to be little evidence of a consist-
ent relationship between perceived locus of control over re-
inforcers (as a stable personality characteristic) and substance
abuse. This is not to imply that control over drugs as re-
inforcers is not relevant to substance abuse. Relationships
between locus of control and specific behavior, e.g., time in
treatment, initiation of voluntary detoxification, have been
found. Drug users report loss of control and maintaining control
to be important reasons for behavior such as entering treatment
and avoiding injection of heroin.
A formulation of need for control over drug use as a central
concern for drug users avoids the problems associated with the
conceptualization of locus of control as a stable personality
characteristic. Perceived control over reinforcers might not be
stable over time; rather, need for control might vary according to
a variety of factors including intensity of present drug use,
psychophysiological adaptations to repeated drug use, availability
of drugs, approval or sanctions from significant others, treatment
status, and the user's self-concept.
Instruments and techniques for measuring need for control are
clearly needed if this concept is to be studied scientifically.
Because need for control is conceptualized as varying across both
persons and situations, instruments similar to the state/trait
measures of anxiety may be required.
After suitable instruments are developed, longitudinal studies of
need for control over drug use will be required. If this need
does vary over time, and if it is an important determinant in drug
use/abuse behavior, then meaningful results are likely only in
studies with time as a variable. Studies that do not include time
as a variable will probably replicate the theoretical confusion
and empirically conflicting data that characterize the present
research on locus of control in drug abuse.
42
REFERENCES
Berzins, J.I., and Ross, W.F. Locus of control among opiate
addicts. J Consult Clin Psychol 40:84-91, 1973.
Carroll. L.T. An Investiaation of the internal and external
control constructs in a-population of patients addicted to
narcotic drugs. University of Kentucky, 1968. Unpublished
doctoral dissertation.
Cohen, H.; Marmot-, M.; Des Jarlais, D.C.; Friedman, S.R.; Mildan,
D.; Yancovitz, S.R.; Mather, U.; El-Sadr, W.; Holtzman, R.; and
Spira, J.J. Behavioral risk factors for HTLV-III/LAV seroposi-
tivity among intravenous drug users. Paper presented at the
International Conference on Acquired Immunodeficiency Syndrome
(AIDS). Atlanta. GA. Aoril 1985.
De Leon; G.; Skodol, A.; and Rosenthal, M.S. Changes in psycho-
logical signs for resident drug addicts. Arch Gen Psychiatry
28:131-135, 1973.
Des Jarlais, D.C.; Joseph, H.; and Dole, V.P. Long term outcomes
after termination from methadone maintenance treatment. Ann NY
Acad Sci 362:231-238, 1981.
Gross, A., and Morosko, T.E. Relation between a dimension of
internal-external control and the MMPI with an alcoholic
population.
Henik, W.,
J Consult Clin Psychol 34:189-192, 1970.
and Domino, G. Selected psychological changes in
heroin addicts undergoing a methadone maintenance treatment
program. J Bronx State Hosp 2:45-50, 1974.
Langrod, J.; Des Jarlais, D.C.; Alksne, L.; and Lowinson. J.
Locus of control and initiation of detoxification among male
methadone maintenance patients. Int J Addict 18:783-790, 1983.
Lefcourt, H.M. Locus of Control: Current Trends in Theory and
Research. Hillsdale, NJ: Lawrence Erlbaum Associates, 1976
New York City Department of Health. AIDS Surveillance Update.
September 25, 1985.
Obitz, F.W.; Oziel, L.; and Unmacht, J. General and specific
perceived locus of control in delinquent drug users.. Int J
Addict 8:723-727, 1973.
Palmer,R.D. Parental perception and perceived locus of control
in psychopathology. J Pers 3:420-431, 1971.
Rotter, J.B. Generalized expectancies for internal versus exter-
nal control of reinforcement. Psychol Monographs 80:1-28, 1966 
Weiss, S.H.; Ginzburg, H.M.; and Goeddart, J.J.
exposure among parenteral drug abusers in New Jersey. Paper
presented at the International Conference on Acquired Immunode-
ficiency Syndrome (AIDS). Atlanta, GA, April 1985.
ACKNOWLEDGMENTS
Support for data collection on the pilot study of intranasal
heroin users was provided by the New York State Division of
Substance Abuse Services, and by the National Institute on Drug
Abuse through grant R01 DA 03574.
43
AUTHOR
Don C. Des Jarlais, Ph.D.
Assistant Deputy Director of Research and Evaluation
New York State Division of Substance Abuse Services
Office of Alcoholism and Substance Abuse
Two World Trade Center
New York, NY 10047
44
Personality Characteristics and
Self-Abusive Behavior
Donald G. Forgays
INTRODUCTION
Five themes are relevant to self-abusive behaviors, notably to-
bacco, alcohol, and drug abuse and, to some extent, overeating.
The themes are:
Self-cure of many of these behaviors occurs much more frequent-
ly than interventional studies indicate.
Self-abusers of various kinds may have distinctive personality
characteristics, and there may be commonality of certain
characteristics across abuse types.
Subjects' differences may be related to ability to change the
abusive behavior, either by themselves or through intervention.
Personality characteristics may be related in somewhat differ-
ent ways to each of the various stages of substance use, abuse,
and cure or fail potential.
Intervention and prevention programs and further research are
clearly indicated by an analysis which emphasizes individual
differences.
While this paper discusses each of these points, primarily the
first three are addressed.
SELF-CURE
Studies of therapeutic attempts to intervene in self-abusive be-
haviors report little success. For example, Leventhal and Cleary
(1980) reviewed smoking intervention studies in which the success
rate was, at best, 20 percent of the smokers. Success was defined
as high reduction or stoppage of smoking 1 year after interven-
tion. Extensive literature reviews are also available for weight
reduction interventions for the obese (Stunkard and McLaren-Hume
1959; Wing and Jeffrey 1979). Only about 20 percent of the obese
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can expect to lose as much as 20 pounds as a result of interven-
tion. The interventional success rate for alcoholism and drug
abuse is expected to be at least as poor as that for smoking and
obesity. In many studies, there is considerable postintervention
improvement in the behavior of concern, but the rate of recidivism
is also great, leaving a small proportion of cures. The dismal
results usually reported for therapeutic interventions in these
behaviors do not support the notion that we know how to manage
these behaviors.
All the more startling, then, are the results of several provoca-
tive studies indicating a much higher level of cure. For example,
Schachter (1982) reports that as many as 60 percent of heavy smok-
ers are able to quit or greatly reduce smoking. He reports a
similar statistic for obese persons who are able to reduce their
weight to nonobese standards. In most of these persons, interven-
tional help was not needed for the change to occur. We recently
attempted to replicate the Schachter study (Rzewnicki and Forgays,
submitted for publication) and found that about 60 percent of our
subjects who were smokers were able to self-cure. The percentage
of our obese subjects who were able to self-manage their weight
was less than that reported by Schachter but higher than that
reported in most of the interventional studies.
In a fascinating recent study, Jeffrey et al. (1982) compared
three formats of a correspondence course with a standard behav-
ioral group program for smoking reduction and for weight manage-
ment. Subjects were randomly assigned to one of the four study
conditions. These authors report that even the basic home corre-
spondence course was as effective as any of the other conditions
and produced significant changes in health behavior. While the
home course is an intervention, of course, the process is close to
self-management.
Other self-abusive behaviors may also be subject to self-
management. For example, Robins et al. (1980) studied a large
number of Vietnam veterans 3 years after they had left Vietnam.
Many had been frequent users of heroin during the war. The
authors reported that users managed to quit using heroin much more
often than general interventional data would predict and, again,
frequently without any special help. They also reported that some
of these former users returned to the use of heroin in this coun-
try and were able to give it up once more without help. Other
important findings in this study were that heroin users tended to
be polydrug users, using all drugs during the same period, and
that they were highly likely to have had serious social problems
before they began to use drugs. Robins and her colleagues con-
cluded that our society has overemphasized the importance of
treatment for heroin and has tended to ignore the severe social
adjustment difficulties that such drug users have.
In an interesting book on de-addiction, Brill (1972) reports
several case histories of heroin addicts who were able to self-
cure. While these individuals indicated that self-management was
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difficult to achieve, they also made it clear that certain per-
sonality characteristics may have helped them to control these
important behaviors.
Several reports have provided data attesting to the voluntary
reduction and cessation of marijuana usage (Brown et al. 1974;
Raffoul and Cummins 1980; Sadava and Forsyth 1977). Most of the
subjects of these studies were college students whose drug reduc-
tions were associated with social psychological changes in their
status, principally life cycle changes and the acquisition of
nonstudent roles. According to the National Commission on
Marijuana and Drug Abuse, 1972, about half of those over the age
of 18 who had used marijuana stopped using it; presumably many of
these were self-cures. Data available from Information Canada
(1972) agrees with this finding very closely.
It has been difficult to find evidence of the self-management of
alcohol abuse. However, Statistics Canada (1981) provides data on
a national sample in which between 5 and 12 percent of drinkers
ceased drinking; presumably this was done on a voluntary basis.
Percentages varied with age and sex of respondent and were higher
for male and older subjects. Even though some of the notions that
Pattison et al. (1977) discuss are controversial, they list 74
studies reporting data indicating that former alcoholics not only
can be "cured' but can even return to controlled drinking without
becoming alcoholics again.
Thus, there appears to be substantial evidence that persons are
able to self-manage important self-abusive behaviors much more
frequently than the interventional literature would predict. One
clear possibility for such large differences in success rates
between self-management reports and the interventional studies is
that subjects in most of the interventional studies are self-
selected and do not represent the self-abuse population. This
point is made emphatically by Schachter (1982) and by Rzewnicki
and Forgays (1985), for smoking and obesity, and by Taylor et al.
(1982) for alcoholism. Indeed, the studies of Schachter and
Rzewnicki and Forgays made use of at least 90 percent of the total
population of their subjects and thus can be seen to represent
well those limited populations. More studies with entire popula-
tions should be undertaken to assess better the distortion factor
involved in self-selected samples.
A second possibility is that subjects in the interview studies of
Schachter (1982) and Rzewnicki and Forgays (submitted for publi-
cation) may have made several attempts at self-management before
attaining success, while intervention seekers are making only a
single attempt, at least in the study proper. Multiple attempts,
especially of motivated self-managers, may be more successful than
a single attempt, especially one that is other-directed.
A third possibility is that the interventional programs that have
been employed to date have been ineffective and may even have
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suppressed change which might have taken place otherwise. This
point will be elaborated shortly.
Thus, if a great number of persons are able to manage many of
these addictive behaviors, largely on their own, we have probably
erred in our research by focusing on the hardcore, intransigent,
and largely self-selected subjects in our interventional studies
and ignoring those who have “cured” themselves. To focus on the
successful may throw light on important subject characteristics,
intervention designs that may be promising, and prevention possi-
bilities. In my laboratory, we have adopted this approach in
ongoing studies of smoking and obesity and are just beginning
similar pilot studies on alcohol and drug abuse.
PERSONALITY CHARACTERISTICS OF SELF-ABUSERS
It is an intriguing notion that self-abusive behaviors occur in
persons who have specific personality characteristics. If this is
so, then information on personality characteristics may point the
way to better design of intervention and prevention programs. Is
there evidence for such relationships? The answer to this ques-
tion seems to be a resounding "yes" with respect to smoking, a
less vigorous "yes' with respect to alcohol and drug abuse, and an
“I don't know" with respect to obesity.
Lilienfeld (1959) has reported that cigarette smokers married more
often, moved more frequently, and changed jobs more often than
nonsmokers. Veldman and Brown (1969) found that smokers were less
well adjusted academically, socially, and physically than non-
smokers, but they state that their smokers did not appear to be
"neurotic." Using his own Personality Inventory on a large number
of middle-aged male subjects, Eysenck (1963) found that his Extra-
version (E) scale was related to cigarette smoking, while pipe
smokers tended to be high on introversion (I). The Neuroticism
(N) scale was not related to smoking level, but those high on the
Neuroticism scale inhaled more deeply. The extraversion finding
was replicated by Smith (1970). In a most unusual study of the
use of maternity services in Britain, all infants born during a
particular week of the year were followed up every 2 years (Cherry
and Kiernan 1976). The Eysenck Personality Inventory was adminis-
tered at the age of 16 years and smoking information obtained at
20 and 25 years of age. These authors confirmed the earlier find-
ing of high extraversion scores for smokers, but also found that
smokers were reliably higher on the Neuroticism scale. The
neuroticism score was also related positively to the degree of
inhalation of smoke. All findings were true for both sexes. In
recent work following up his earlier studies, Eysenck (1980) again
found that smokers were higher than nonsmokers on the Extraversion
scale but that only his female subjects were higher on the Neurot-
icism scale. Smokers were also higher than nonsmokers on his new
Psychoticism (P) scale. While there are small differences in the
findings of several studies employing the Eysenck scales, the
principal findings appear to be robust.
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Zuckerman (1979) reported mixed results with respect to the rela-
tionship between smoking and scores on his Sensation Seeking
Scales, with some studies finding higher sensation-seeking scores
but only for male smokers, not females; other studies found the
reverse. Zuckerman suggested that these mixed results might
reflect different motives for smoking--smoking for arousal might
occur in high sensation-seeking persons, while smoking to relieve
social tension might occur in low sensation-seeking persons.
Friedman et al. (1975) attempted to relate cigarette smoking to
myocardial infarction. They were not able to confirm a direct
relationship but concluded that smoking as a coronary risk factor
may vary with psychological status of the person.
The general picture of the relationship between smoking and per-
sonality characteristics has been summarized recently by Ashton
and Stepney (1982). Smokers tended to be high on Eysenck's scales
of Extraversion and Neuroticism. They tended to be high risk
takers, and have higher impulsivity and internal sensation
seeking. They also tended to be high on Eysenck's Psychoticism
scale, which may measure a dimension related to sensation seeking.
In general, heavy smokers are poorly integrated persons.
Only a small amount of information is available on the personality
characteristics of alcohol abusers. Schwarz et al. (1978) found
that sensation-seeking score in college-aged subjects was strongly
and positively related to alcohol use, while a measure of anxiety
was not. In these subjects, alcohol appeared to serve as a
"releaser" for normally restrained social behavior. Zuckerman
(1979) reported that persons with high sensation-seeking scores
were more likely to try any drug, including alcohol. He reported,
however, that alcoholics were not high scorers on his scale but,
rather, scored at their normal age levels. The differences
between these two reports may simply be the difference between
alcohol users and alcohol abusers, but they also suggest develop-
mental differences which should be investigated in a longitudinal
design.
Are there unique personality characteristics of the drug abuser?
Sutker et al. (1978) reported that drug addicts as a group were
high on the Adjective Check List scales of Aggression and
Succorance. Zuckerman (1979) found that persons with high
sensation-seeking scores were more likely to try any drug than
persons with low scores. He reported that high sensation seekers
in both student and nonstudent groups were more likely to experi-
ment with a variety of drugs, starting with marijuana. Sensation
seeking was found also to be related to drug use in college stu-
dents by Galizio and Rosenthal (1983). A similar finding has been
reported by Khavari et al. (1977), who studied several hundred
male and female members of labor unions. They found that while
results depended upon the specific type of drug used, the use of
psychedelics was strongly associated with the need of their sub-
jects to seek out new and often unconventional experiences. Other
findings were that marijuana users were different from users of
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other drugs in that they seek social approval and display un-
inhibited modes of self-expression, while the use of other psyche-
delics was associated with higher manifest anxiety, tendencies to
seek out social stimulation, and extraversion, but not with
approval seeking or uninhibitedness.
Recent research on prediction of addiction behavior, including
alcohol abuse, has made use of the MacAndrew Scale (MacAndrew
1965; MacAndrew 1979; Rathus et al. 1980). This is an empirically
derived scale based on the Minnesota Multiphasic Personality
Inventory (MMPI). It appears to be a measure of impulsivity, risk
taking, high energy and activity, interest in excitement and
stimulation, and so on. The MacAndrew Scale reminds one of the
Sensation Seeking Scales and of Eysenck's Psychoticism scale.
Wisniewski et al. (1985) have found this measure to be the best
single predictor, as compared with a variety of sociodemographic
variables, of alcohol and drug use for both male and female
subjects.
The picture emerging in these studies appears to be that of a
personality profile in which important characteristics are shared
by self-abusers of tobacco, alcohol, or illegal drugs. The pro-
file is one of high extraversion, probably some neuroticism, high
impulsivity, high risk taking, and a strong need to seek out new
and unconventional experiences. There are likely to be sex,
developmental, and social-class differences within this generic
profile.
The familiar chicken-egg issue permeates these relationships. Do
persons having this profile gravitate to abusing situations or
does abuse lead to the expression of the profile characteristics?
The literature has too little data on this issue. However, the
Cherry and Kiernan (1976) research is quite clear on the matter
with respect to smoking. Personality measures at age 16 and smok-
ing measures at ages 20 and 25 showed that potential smokers had
high extraversion and neuroticism scores before they took up
smoking. Thus, it appears that we may be able to predict later
self-abusive behavior from earlier personality measures.
PERSONALITY CHARACTERISTICS AND CHANCE POTENTIAL AMONG
SELF-ABUSERS
If self-abusers share some personality characteristics which exist
before the self-abuse, it would be interesting to know whether
personality characteristics can also be related to the ability of
an abuser to reduce or stop the abuse. While most such evidence
exists for smoking, some does relate to alcohol and drug use.
Some of the smokers in the Cherry and Kiernan (1976) study had
given up smoking by the time they were 25 years of age. What were
they like? In general, they were extraverts who did not smoke at
a high daily level. Specifically, male extraverts who were stable
on the Neuroticism scale and who smoked at a low level were most
likely to give up smoking; 47 percent of this group were able to
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do so by age 25. This proportion drops to 2 percent for the neu-
rotic introverts who smoke at a high level.
Friedman et al. (1979) compared ex-smokers, continuing smokers,
and nonsmokers in a large number of white and black male and
female members of a health maintenance program. As compared with
continuing smokers, smokers who quit had fewer cardiovascular
symptoms, smoked fewer cigarettes for a shorter time, inhaled
less, were better educated, consumed less alcohol, and differed on
several other physiological indices. On a measure derived from
the MMPI (not described well in the article), quitters and never
smokers scored lower than the persistent smokers. The answers of
quitters in the 155 items on this scale were not like those who
later developed myocardial infarction. The authors conclude that
quitters are more analogous to never smokers than to persistent
smokers on several of their indices, including their personality
measure.
In his recent book, Eysenck (1980) reports his own data on never
smokers, persistent smokers, cured smokers, and failed smokers,
using his Eysenck Personality Questionnaire (EPQ) measure. He
found significant differences among these four groups on the
Psychoticism, Extraversion, and Neuroticism scales, but not on the
Lie scale. There were no reliable sex by group interactions. If
his data are combined across the sexes, the personality measures
for the four groups are as follows:
Those who never smoked have middle values on the Psychoticism
scale, middle values on the Extraversion scale, and low values
on the Neuroticism scale.
Those who persist in smoking have high values on the P scale,
quite high on E, and quite high on N.
Those who try but fail to quit smoking have the highest P
scores, the highest E scores, and the highest N scores of the
four groups.
Those who quit smoking have the lowest P scores, lowest E
scores, and somewhat elevated N scores.
Two relationships stand out in these data. The first is that
persistent smokers and failed smokers are similar in their pro-
files on this measure and score highly on all three scales, with
the failed smoker scoring somewhat higher than the continuing
smoker who does not try to stop. The second is that the cured
smoker is similar in profile to the never smoker, with the never
smoker being somewhat higher on the P and E scores and the cured
smoker being somewhat higher on N.
A recently completed smoking intervention study provided heavy-
smoking subjects with flotation relaxation in various time distri-
butions, with or without messages that were attempts to modify
their attitudes about smoking (Forgays, in press). There were two
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waiting-list control groups; one received the messages over the
telephone and the other did not. All subjects took a battery of
personality tests before active intervention, and each was fol-
lowed for over a year to see whether or not any changes in smoking
behavior had taken place. We found, at l-year followup, that our
relaxation groups had reduced their smoking behavior to an extent
considerably greater than that most frequently found in the smok-
ing intervention literature. To our surprise, however, we found
that our control subjects had reduced their smoking even more,
especially the group that had the least contact with us. Since we
found that there were quitters in each of the study groups, per-
sons who had reduced smoking appreciably, and subjects whose smok-
ing patterns were unchanged, we decided to compare these three
groups on the various personality measures. Remember that each of
these new groups represents all six groups of the original study.
The personality measures we employed included the Eysenck Person-
ality Inventory (EPI), the Sensation Seeking Scales (SSS), the
Spielberger Trait Anxiety Scale, the Manifest Anxiety Scale, the
Rotter Locus of Control measure, the Jenkins Activity Scale,
Oerogatis' Symptom Check List-90, and Morris' Ways-to-Live
measure.
In comparing the cures with the reducers with the persistent
smokers, the following profile emerged:
On the EPI, the cures were somewhat higher, though not reliably
so, on the Extraversion scale, but were reliably higher on the
Neuroticism scale than were the reducers and the continuing
smokers.
On Zuckerman's SSS, the cures and the reducers were reliably
higher than the persistent smokers.
On the Spielberger Trait Anxiety Scale, the cures scored higher
anxiety than the continuing smokers.
No reliable differences were found on the Manifest Anxiety
Scale, but the cures showed more anxiety than the reducers, who
in turn showed more anxiety than the continuing smokers.
Average scores for the three groups of subjects were about the
same on the Locus of Control measure.
On the Jenkins Activity Scale, reliable differences placed the
cure subjects in the direction of Type A (63 percent score),
reducers about average (44 percent), and persistent smokers in
the direction of Type B (34 percent). Let me emphasize that
cures are not Type A and continuing smokers Type B. The scores
are not that extreme, but they are significantly different in
these directions.
On the Symptom Check List-90, the cure group is reliably less
stable, more somatic, more obsessive-compulsive, and more
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anxious than the other two groups, and the reducers tend to
have more of all these characteristics than the continuing
smokers. Again, I wish to emphasize that these scores are not
that extreme; that is, the cures are not emotionally dis-
ordered, but they are notably different from the other
subjects.
On the Morris Ways-to-Live measure, the cure group displays a
low self-sufficiency pattern but also a high attraction to many
different ways to live their lives, compared with the other two
groups.
Based on this study, then, the general personality profile of
cured smokers is that they tend to be somewhat emotionally un-
stable, score in the direction of Type A, and are somewhat more
anxious than the persistent smokers. They are more obsessive-
compulsive, have more somatic complaints, are less secure, are
more independent of others in making decisions, and like to do new
and different things more than do the continuing smokers. The
reduced smokers tend to be in between the cures and the persistent
smokers on most of these dimensions.
For alcohol abusers, the data are more sparse. McGovern and
Caputo (1983) report that the most significant predictor of treat-
ment outcome for inpatient alcohol detoxification is the locus of
control score. Internalizers on this scale tend to be more
successful than externalizers in treatment outcomes. This finding
would appear to be in accord with the review findings of Craig
(1979).
In an interesting study, Hurlburt et al. (1984) compared Alcohol-
ics Anonymous members with nonmembers who were alcoholics, on
Eysenck's EPQ scale. They found that members were higher on the
Extraversion scale, but lower on the Neuroticism and Psychoticism
scales.
Billings and Moos (1983) studied psychosocial processes of re-
covery among alcoholics and their families. They found that
patients who controlled their drinking showed improvements in
nondrinking aspects of their functioning, and members of their
families showed improved adjustment as well. These recovered
families were comparable to matched nonalcoholic families in
posttreatment functioning. The relapsed alcoholics and their
families suffered from multidimensional impairments. While they
did not report on personality measurement as such, it seems clear
from their data that the coping behaviors and social resources of
these controlled alcoholics and their families, as well ,as the
environmental stressors impinging on them, had as much influence
on the recovery process as the treatment experiences.
There is little information on sensation-seeking scores of recov-
ered vs. relapsed alcoholics. Zuckerman's (Zuckerman 1979) find-
ing of average SSS scores for alcoholics would not predict such
differences, perhaps, but study of the various alcohol groups,
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nonuser and abuser, failed and cured, should be undertaken with
this instrument.
Data on the personality characteristics of drug users and non-
users, ex-users and failed users, are sorely lacking. Designs of
the sort described above in the smoking change studies should be
undertaken as soon as possible.
While many gaps exist in the data on change of abusive behavior,
the studies described at least suggest strongly that personality
characteristics are involved in the process.
PERSONALITY CHARACTERISTICS AND THE STAGES OF SELF-ABUSE
AND CHANGE
One of the difficulties encountered in the past in attempting to
relate personality measures to self-abusive behavior may be the
tendency to ignore the possibility that different personality
dimensions relate to different stages of abuse. In other words,
the kinds of factors that lead to abuse may be somewhat different
from those conducive to maintenance behavior, which again may be
different from those associated with later change. The picture
may be a delicate one, bludgeoned with simplistic research designs
and a quest for a magic bullet; i.e., uniform treatment plans for
substance abuse problems.
For example, Cherry and Kiernan (1976) found that neurotic extra-
verts would be more likely to start smoking cigarettes, while sta-
ble extraverts would be more likely to stop smoking. Ashton and
Stepney (1982) suggested that peer influence was very important in
starting to smoke but that other factors, largely personality
ones, were related to stopping. Keup (1982) reported that socio-
logical reasons (friends, relatives, and media influence) and
psychological reasons (curiosity, enjoyment, novelty, escape)
accounted for virtually all the initiation of drug abuse in the
subjects he studied. Sadava and Forsyth (1977) found that
initiation to cannabis use was largely due to social variables,
including social support, sibling models, and the like, while
personality variables were largely responsible for the user's
stopping the abuse. They found that subjects who were able to
stop were less conforming and more independent and that social
variables were not important. Social factors regain their impor-
tance in relapses to drug use which may occur.
Admittedly, the information above is only suggestive. However,
it suggests the possibility of differential dynamics related to
initiation of abuse, perhaps to maintenance of the abuse, and to
later change. Research designs in the future should take these
distinctions into account, especially in investigations of
personality characteristics related to abuse pattern.
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INTERVENTION, PREVENTION, AND FURTHER RESEARCH
Does the analysis provided suggest intervention, prevention, and
further research programs which might be applied to self-abusive
behavior? I believe it does.
In planning therapeutic interventions for such behaviors, we
should take the personality characteristics of the clients into
account. Zuckerman (1979) suggested that we take sensation-
seeking score into such account. Cherry and Kiernan (1976) stated
that the practical use of their data would include the possibility
of allocating clients to different types of smoking clinics. Our
own research and that of Eysenck (1980) suggests that matching of
client to interventional program will likely be a more successful
procedure than attempts to provide a uniform program for all
comers; The possible mismatching provided in past interventional
programs may be responsible, in part, for the mixed results
obtained. It is possible that, under these circumstances, thera-
peutic intervention may be actually inhibitory for some clients,
or perverse, as Schachter (1982) has called it.
For prevention programs, again the key word is matching of cam-
paign to type of subject, following the logic that a uniform
program may not be meaningful for subjects with different person-
alities. Cherry and Kiernan (1976) have proposed that their kinds
of results should be incorporated in the design of antismoking
propaganda. Zuckerman (1979) has suggested that sensation-seeking
score might lead us to provide choices for high sensation seekers
other than drugs or crime; such choices might provide unusual
experiences in occupations or entertainment avenues. Indeed, it
might be less expensive to send kids to Disneyland than to provide
high-level therapy programs, especially if they do not work.
To take such a view of prevention is to bend the disease model
followed lately. Rather than await the display of self-abusive
behaviors and then jump in with therapeutic attempts to "cure the
disease," we should, perhaps, consider a prevention paradigm,
whether the inoculation is socially or physiologically based.
For research, I propose an epidemiological approach to these
issues. For each abusive behavior, we should study those who have
the behavior, and those who do not have it; those who have changed
the behavior, with and without intervention; and those who have
failed to change it. We should certainly pay as much attention to
the cases of success as to the failures. And we should emphasize
and measure carefully individual differences among subjects, as
Eysenck (1981) has recently pointed out. We should attend to the
time course of self-abusive behavior and should break down our
analyses into the initiation, continuance, and change stages. All
of this should be done in carefully controlled studies.
Nothing said here precludes the inclusion of a variety of physio-
logical measures. There must be physiological substrata to these
behaviors, whether correlative or causal, and these substrata
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should be investigated. Neither has anything been said that pre-
cludes the possibility of important genetic contribution to the
development of such behaviors, likely through the influence of
physiological processes that may underlie specific personality
characteristics.
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Sensation Seeking and the
Endogenous Deficit Theory of
Drug Abuse
Marvin Zuckerman
INTRODUCTION
Sensation seeking is a personality trait that is central to an
understanding of the biological disposition toward drug abuse.
The general definition of the trait is:
the need for varied, novel, and complex sensations and
experiences and the willingness to take physical and
social risks for the sake of such experience.
(Zuckerman 1979, p. 10)
The most frequent reasons given by users of many drugs, including
marijuana, narcotics, and hallucinogens, were "to experience some-
thing new" or "curiosity" (Segal et al. 1980). Thus, the primary
motive given by the drug users themselves sounds like the trait we
have called "sensation seeking." More important, sensation seek-
ing has been shown to be the personality trait that is most
consistently and highly related to most types of drug use and is
most highly discriminating in comparisons of drug abusers with
control populations (Kilpatrick et al. 1976; Segal et al. 1980;
Zuckerman 1972; Zuckerman 1979; Zuckerman 1983a). Furthermore,
sensation seeking is based on a psychobiological theory that
offers a psychopharmacological model for the biological basis of
the trait (Zuckerman 1979; Zuckerman 1983a; Zuckerman 1984a;
Zuckerman et al. 1983b). Together with traits like extraversion
and impulsivity, sensation seeking has been related to the enzyme
monoamine oxidase (MAO), which points to the role of central mono-
amine systems in the trait. MAO, in turn, has been related to
drug use and other risk-taking activities. All these topics will
be addressed in more detail in this paper.
THE SENSATION SEEKING SCALES (SSS)
The first published form (II) of the SSS contained only a General
scale, based on a factor analysis of a broad variety of items
written to fit the hypothesized trait (Zuckerman et al. 1964).
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The second versfon, form IV (Zuckerman 1971), based on more exten-
sive factor analyses, contained four subscales:
(1) Thrill and Adventure Seeking (TAS): The desire to try risky
sports or activities involving elements of speed, movement,
and defiance of gravity.
(2) Experience Seeking (ES): The desire to seek experience
through the mind and the senses; through music, art, travel,
and an unconventional style of life with unconventional
friends.
(3) Disinhibition (Dis): The desire for or actual enjoyment of
uninhibited and socially extraverted activities, e.g.,
parties, social drinking, and a variety of sexual partners.
(4) Boredom Susceptibility (BS): A strong aversion to monotony
or a lack of change, and a preference for the unpredictable;
restlessness in confining, dull conditions.
Forms IV and V contain scales based on these factors. Form IV
also contains the General scale carried over from form II. Form V
(Zuckerman et al. 1978) contains a balanced scale of 10 items
representing each of the factors and a Total score based on all 40
items. Form VI (Zuckerman 1984b) contains only TAS and Dis scales
arranged in two sections: one dealing with past experience in
sensation-seeking activities, and the other with intentions for
future activities.
The many studies establishing the reliability and validity of the
SSS have been summarized elsewhere (Zuckerman 1978; Zuckerman
1979; Zuckerman 1983a; Zuckerman 1984a). The SSS have been re-
lated to a wide variety of risk-taking activities and a preference
for novelty, complexity, and intensity in cognitive styles, art,
music, reading, and media presentations. Biological correlates
have been found in psychophysiological and biochemical phenomena
(Zuckerman et al. 1980), and a large twin study (Fulker et al.
1980) has shown a relatively strong genetic determination for the
trait.
Sensation seeking has been correlated with many other personality
traits (Zuckerman 1979) including locus of control. Few signifi-
cant relationships have been found between the SSS and locus of
control in college student populations. In patient and prisoner
groups the ES, Dis, and BS scales have shown positive relation-
ships with the Locus of Control scale, indicating that high sensa-
tion seekers of these types tend to believe in an external locus
of control. Of course, in prisoners and hospitalized patients
this belief would be quite realistic in terms of their current
situations.
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SENSATION SEEKING AND DRUG ABUSE
Previous articles have reviewed the area of sensation seeking and
drug and alcohol use (Zuckerman 1972; Zuckerman 1983b). Since two
of the SS scales contain some reference to drug use (ES and Dis),
correlations with these scales alone would be suspect. But in an
early study (Zuckerman et al. 1972), drug use correlated with the
General and all the subscales in college females, and with all but
the Dis scale in males. The Dis scale correlated with the extent
of alcohol use in both sexes. Segal et al. (1980). using large
samples of 1,095 college students and 350 naval personnel, found
the ES and Dis scales to be the most highly predictive of drug use
compared to other personality scales, including the Locus of
Control scale. The ES scale was consistently the best predictor
in all analyses in the college groups; the Dis scale was the best
one in two of the three Navy groups. The drug-relevant items had
been removed from the SSS before analysis so that the results
could not be attributed to content confounding. Findings with the
Locus of Control scale were inconsistent from sample to sample,
and differences between groups were small.
Kilpatrick et al. (1976) compared nonusers, occasional, and regu-
lar users of alcohol and/or drugs in hospitalized veterans. A
variety of personality trait measures were used, including the
Locus of Control scale. As in the Segal et al. study, the SS
scales, particularly ES, Dis, and BS, were by far the best con-
current predictors of regular drug use. The Locus of Control
scale did not differentiate among the groups.
Specific Drug Use
According to the earlier optimal level theory (Zuckerman 1969),
sensation seekers should be more prone to use drugs of all types;
among drug users, the higher sensation seekers should prefer drugs
that stimulate high cortical arousal levels rather than drugs that
depress arousal. In the Zuckerman et al. (1972) study, high sen-
sation seekers were distinguished from mediums and lows on use of
marijuana, hashish, amphetamines, cocaine, and LSD, but not on
barbiturates, opium, heroin, demerol, morphine, or tranquilizers.
Khavari et al. (1977) found that the SSS correlated with use of
marijuana. hashish, and LSD in members of a labor union. However,
there were not many users of heroin in these groups. Kaestner et
al. (1977) discovered that sensation seeking was related to vari-
ety of drugs used by former drug abusers but not to the specific
drugs used. Carrol and Zuckerman (1977) found low but significant
positive correlations between use of stimulants and hallucinogens
and the Dis scale in a former drug abusing group, in contrast to a
lack of correlation with use of depressant drugs. Skolnick and
Zuckerman (1979) compared hard drug (mostly heroin) and soft drug
(polydrug including stimulants) users and found that the soft drug
users scored higher on SS scales. Despite these findings showing
some relationship between sensation seeking and a preference for
stimulant drugs, other findings suggest that young heroin users
are high sensation seekers relative to their peers (Platt and
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Labate 1976) and that high and low sensation seekers do not react
differently to stimulant and depressant drugs (Carrol et al.
1982). However, results on the biological bases of sensation
seeking (Zuckerman et al. 1980) have led to a new model for the
trait that goes "beyond the optimal level of arousal" of the
cortex and suggests that drugs are used because of their effects
on neurotransmitters whose activity at moderate levels is
rewarding (Zuckerman 1979; Zuckerman 1983b; Zuckerman 1984a).
BIOCHEMICAL CORRELATES OF SENSATION SEEKING
Gonadal Hormones
Sensation seeking, particularly on the TAS and Dis scales, shows
consistent age and sex differences: males are higher than fe-
males, and scores on these scales decline with age (Zuckerman et
al. 1978; Zuckerman and Neeb 1980). These data suggested that
high sensation seekers might have higher levels of testosterone
than lows, even within sexes. Daitzman et al. (1978) found posi-
tive correlations between the Dis scale and plasma androgen and
between the Dis scale and plasma estrogen as well, the latter an
unexpected finding. The findings were confirmed in a second study
(Daitzman and Zuckerman 1980), in which subjects were selected for
high or low Dis scores. The high Dis subjects were significantly
higher than low Dis subjects on plasma testosterone, 17-ß-estra-
diol. and estrone. Testosterone also correlated positively with
scales of sociability, impulsivity, and heterosexual experience,
and negatively with neuroticism scales. Estradiol loaded posi-
tively on a factor defined by social deviancy on the positive end
and social conformity at the negative end. Although measures of
drug use were not included in this study, one would predict that
among males drug use, like sensation seeking, would be related to
both testosterone and estradiol. The testosterone is related to
the normal impulsive extraversion, while the estradiol adds a fac-
tor of social deviance that may lead to antisocial activities.
Schalling et al. (in press) reported that plasma testosterone
correlated with scales of Monotony Avoidance (sensation seeking),
aggression, sociability, and preference for physical sports in a
group of delinquent boys.
Monoamine Oxidase (MAO)
MAO is an enzyme that regulates the three monoamine systems in the
brain. A low level of MAO, measured in blood platelets, has pro-
vided an interesting biological marker for various psychiatric
disorders, as well as showing significant relationships with per-
sonality and antisocial, risk-taking behaviors in humans, activity
levels in human neonates. and sociable and dominant behaviors in
humans and monkeys (Zuckerman et al. 1980). Low levels of MAO
have been found among chronic alcoholics and marijuana users, and
low MAO males in normal populations report using more drugs and
smoking more cigarettes than high MAO types (Coursey et al. 1979;
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von Knorring and Oreland 1985; von Knorring et al. 1984). Plate-
let MAO is a stable and reliable measure, and one that shows
strong genetic determination in twin studies.
Six studies involving nine groups of subjects have reported corre-
lations between MAO and the SSS. In all but one of these groups
the correlation was negative, and in six of the nine groups the
negative correlation was significant. There is a very large range
in the magnitude of the significant correlations, from -.06 to
-.66, and the median of the correlations is only -.25. However,
the unquestionable existence of the finding, despite the fact that
some of the studies were done in Sweden and Spain using translated
SS scales and different kinds of subject populations, is inter-
esting. Four studies have been done involving six groups and
using the Swedish Monotony Avoidance (MAv) scale. All the corre-
lations were negative, and three of the six were significant
despite the fact that the median correlation was only -.22. Four
of the samples involved depressed patients, and in three of the
four the negative correlation was significant.
It should not be surprising that the typical correlations between
biological and personality traits are low. Personality may be
affected by MAO in the brain, but we are measuring a marker in the
blood. The actual correlation between platelet and brain MAO is
not known, although MAO levels in different parts of the brain
correlate fairly highly. However, there must certainly be an
attenuation of the correlation between brain MAO and the sensa-
tion-seeking trait. Even though the platelet MAO measure is fair-
ly reliable, there is some change, as there is for the personality
measure. Above all, it would be foolish to expect that a complex
personality trait would be determined solely by a single brain
enzyme. MAO is one element in at least three complex neuro-
transmitter systems. While it may have some influence on the
activities of these systems at any given time, there are other
enzymes, receptors, and interactions between the systems them-
selves that would also be affecting the activity in each of the
systems. The wonder is not that the correlation is low, but that
it exists at all. What low MAO may indicate is that one of the
factors that stabilize the neurotransmitter systems related to
behavioral arousal (dopaminergic and noradrenergic systems) is in
deficit; therefore, we might expect large fluctuations in behavior
and mood and a failure of negative feedback mechanisms to control
these. One example is the bipolar or manic-depressive disorder
for which sensation seekers are at risk (Zuckerman 1985). The MAO
findings point to the monoamine systems as being involved in sen-
sation seeking and related traits such as impulsivity. Studies
have just begun which generally use metabolites of the brain
neurotransmitters: norepinephrine, dopamine, and serotonin.
These few studies will be discussed next.
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Monoamines and Their Metabolites
One of the effects of stimulant drugs such as amphetamine and
cocaine is a potentiation of the catecholaminergic systems
(dopamine and norepinephrine) in the brain. The euphoria and
energy that is initially produced by these drugs may be a function
of the increased activity in these systems and their activating
effects on the cortex. The opiate drugs undoubtedly act on the
opiate receptors, which normally respond to the endogenous opiates
(endorphfns) in the brain. Could the attraction of these drugs
lie in the normal state of the systems that they act upon? I will
return to this question later. First, let us examine the evidence
relating sensation seeking and other traits to the monoamines.
A study by Ballenger et al. (1983) examined the relationships of a
wide range of biochemical variables to normal and abnormal person-
ality traits, including sensation seeking, in a group of screened
normal subjects. Age and body size (height and weight) were con-
trolled through the partial correlation method. Sensation seeking
was negatively correlated with plasma dopamine-beta-hydroxylase
(DBH) and norepinephrine (NE) in the cerebrospinal fluid (CSF) in
males and females and in the total group. The negative correla-
tion with DBH was found in two other studies (Kulcsar et al. 1984;
Umberkoman-Wiita et al. 1981). Both the DBH and NE findings would
indicate underactivity in the noradrenergic system in high sensa-
tion seekers, since DBH is the enzyme involved in the conversion
of dopamine to NE in the NE neuron.
Schalling et al. (1984) concentrated on CSF metabolites of sero-
tonin (5-HIAA), dopamine (HVA), and norepinephrine (MHPG) in their
study of the relationships between monoamines and personality
traits in normals and patients. The serotonin metabolite, 5-HIAA,
correlated negatively with Eysenck and Eysenck's (1975) P scale in
the normal and two of the three patient groups. Although the
Eysencks have used the term "Psychoticism' to describe what this
scale measures, some factor analyses that we have completed
recently suggest that the P factor reflects unsocialized and
impulsive, sensation-seeking tendencies. If one wants to use a
diagnostic label for the scale, "Psychopathy" might be a better
one than Psychoticism. Persons scoring at the extreme on this
scale are liable to engage in unconventional and sometimes anti-
social activities and would be expected to be among those experi-
menting with illegal drugs. The fact that high P scorers in the
normal and patient populations tend to be low in serotonin is
interesting in view of the clinical and comparative data. Low 5-
HIAA levels have been found in the brains of those committing
suicide and in the CSF of those attempting suicide, particularly
when the attempts are violent in nature (Lidberg et al. 1985).
Low levels of the metabolite have also been found in impulsive
murderers. The animal literature on serotonin depletion suggests
that serotonin serves to inhibit behavior in conflict or frustra-
tion situations. A deficit in serotonin is associated with impul-
sivity and a failure to inhibit behavior even in the face of
anticipated punishment. Remembering the definition of sensation
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seeking as the "willingness to take risks," one might expect the
Monotony Avoidance scale to be related to 5-HIAA. It was nega-
tively related to 5-HIAA in all three patient groups, but the cor-
relation was not significant in the normal group. The dopamine
and NE metabolites showed little relation to personality in this
study, although the dopamine metabolite, HVA, correlated negative-
ly with P and showed some low negative correlations with Monotony
Avoidance, as did MHPG.
A third major study, done at the Autonomous University of
Catalonia (Arque et al. 1985), used only indices available from
blood, but one of these, plasma MHPG, is regarded as a fair indi-
cator of central noradrenergic activity. This measure correlated
negatively with Total, ES, and Dis SS scales in a normal group,
but not in a somatoform patient group. Although these findings
are consistent with the negative CSF-NE vs. SSS correlation in the
Ballenger et al. (1983) study, that study also used plasma MHPG
but found no significant correlations between this measure and SS
scales.
Endorphins
In a prior section, I commented on the fact that young heroin
users were also high sensation seekers, relative to their delin-
quent peers. There are greater risks entailed in heroin use than
in most other types of drugs. The legal penalties are more.
severe, and the expense of supporting a strong habit usually
necessitates criminal activity. Most users are aware of friends
who have "OD'd" (overdosed) and died as a consequence. Perhaps
the high sensation seeking in heroin users simply reflects the
greater readiness to assume the risks entailed in the search for
the sensations of euphoria. As tolerance develops, the high
euphoria of the "rush" is harder to achieve, and the user may
settle for the modest but more prolonged euphoria of the "nod-
ding." Since the opiates act on endogenous opiate receptors, it
is possible that a lack of endogenous opiates, or endorphins, may
make exogenous opiates particularly attractive to those with such
a biological disposition. This possibility makes the levels of
endorphins in sensation seekers a matter of interest in explaining
why sensation seekers might abuse drugs whose primary effects are
depressant rather than stimulant. Stein (1978) and others have
suggested that there are two types of reward mechanisms in the
brain: arousal reward associated with activity of the catechola-
mine systems, and arousal reduction reward related to the
endorphin systems.
A study by Johansson et al. (1979) reported significant negative
correlations between CSF endorphins and two of the SS scales, Dis
and BS, suggesting that those high on these more antisocial kinds
of sensation seeking might suffer from a lack of endogenous
opf ates . However, the finding was not in drug abusers but in a
sample of patients suffering from chronic pain of either a psycho-
genic or organic origin. The study by Ballenger et al. (1983) in
non-drug-abusing normals failed to find any relationships between
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sensation seeking and either endogenous opiates or beta-endorphin.
Studies of levels of endorphfns in former heroin abusers, who are
currently drug free, would be illuminating.
Other Biochemical Findings
Two new findings have recently emerged from the study by Arque et
al. (1985). Thyroid-stimulating hormone (TSH) was negatively cor-
related with Total SSS in both normals and somatoform patients.
The implication of this finding might be a high level of thyroid
hormone in high sensation seekers or a low level of the hormone in
low sensation seekers. These investigators did find a significant
positive correlation between T4 and the TAS scale in normals, but
not in patients in whom the correlation was low and negative.
Reexamination of unreported data in the Ballenger et al. (1983)
study revealed significant negative correlations between T4 and
both the TAS SS scale and the Eysenck Extraversion scales.
The Spanish investigators (Arque et al. 1985) also found signifi-
cant negative correlations between acetylcholinesterase (ACH) in
both normals and patients. Acetylcholine systems in the brain
have been associated with arousal mechanisms, aggression (muri-
cidal) in rats, and depression in bipolar affective disorders.
Physostigmine, a potent cholinesterase inhibitor, is reported to
ameliorate manic symptoms (Janowsky et al. 1972). ACH terminates
activity in the cholinergic system at the postsynaptic membrane.
A deficit of ACH in high sensation seekers might have some role in
the relationship of the trait to bipolar disorder and manic
behavior.
These preliminary findings may be signs that we must look beyond
the monoamine systems for a full explanation of the sensation-
seeking trait.
ENDOGENOUS DEFICIT THEORY OF DRUG ABUSE AND SENSATION SEEKING
It is interesting that most of the correlations between sensation-
seeking and neurotransmitters and neuroregulators are negative in
sign. In my Behavioral and Brain Sciences article (Zuckerman
1984a), I suggested that sensation seekers might seek stimulant
drugs because they are low in tonic catecholamine system activity
and need such drugs to bring this activity up to an optimal level
where they feel and function best. The significance of the low
MAO levels in sensation seekers and bipolar disorders, as well as
in impulsive personalities (Schalling and Asberg 1985), may be a
lack of regulation in monoamine systems leading to a positive
feedback of sensation-seeking behavior. The low sensation seekers
may have a strong biochemical negative feedback which would dampen
sensation-seeking activity if it ever got started.
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NEW METHODOLOGIES AND THEIR POSSIBILITIES
I have noted how limited the current methodologies are in answer-
ing the questions concerning neurotransmitter actions in the brain
from levels of peripheral transmitters and metabolites. The new
developments in Positron Emission Tomography (PET) offer the
possibility of observing the activity of these systems in vivo in
the brain. Haier (1985) has already reported some preliminary
findings using the PET scan on persons given the Sensation Seeking
and other personality scales. Future research using neuro-
chemically selective emission tomography could answer many of the
questions that have been raised about the link between sensatfon
seeking and drug abuse. Such research is expensive, but the
payoff--a basic understanding of what motivates people to derange
their neurons with potentially damaging substances--may be well
worth the price.
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Control Vs. Lack of Control Over
Aversive Stimuli: Nonopioid-Opioid
Analgesic Consequences
Robert C. Drugan and Steven F. Maier
INTRODUCTION
It is now well established that the behavior, physiology, and
stress pathology resulting from experience with noxious stimula-
tion is markedly dependent upon the organism's control vs. lack of
control over the aversive event. The initial finding of differ-
ential impact of controllable vs. uncontrollable electric shock
was demonstrated by Seligman and Maier (1967). Subjects that were
unable to control an environmental stressor such as electric shock
showed many deleterious effects of the stress experience. Con-
versely, if the subjects were able to control or "cope" with the
stressor, then none of these stress pathologies were observed,
The concept of control can be characterized as the ability, or
lack of ability, to alter the onset, termination, duration, inten-
sity, or pattern of an aversive experience. In the experiments
reported here, control over shock was accomplished by allowing the
subject to turn a wheel in the behavioral chamber in order to
terminate shock.
BEHAVIOR AND STRESS CHANGES PRODUCED BY INESCAPABLE SHOCK
The many stress pathologies or deficits observed following expo-
sure to inescapable but not escapable shock have been referred to
as "learned helplessness" effects (Seligman and Maier 1967; Maier
and Seligman 1976). These deficits include: failure to learn to
escape shock in a different situation where escape is indeed pos-
sible (Seligman and Maier 1967; Maier and Seligman 1976), subse-
quent inactivity in the presence of shock (Anisman et al. 1978;
Drugan and Maier 1982; Drugan and Maier 1983; Jackson et al.
1978), reduced aggressiveness and dominance in a variety of situa-
tions (Maier et al. 1972; Payne et al. 1970; Powell and Creer
1969; Rapaport and Maier 1978), enhanced susceptibility to growth
of implanted tumors (Sklar and Anisman 1979; Visintainer et al.
1982), development of gastric ulcers (Weiss 1971), and immuno-
suppression (Laudenslager et al. 1983).
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On a neurochemical level, inescapable but not escapable shock has
been shown to produce significant alterations in norepinephrine
(Weiss et al. 1981; Anisman and Sklar 1979), dopamine (Anisman et
al. 1981), serotonin (Sherman and Petty 1982), acetylcholine
(Anisman and Sklar 1979; Anisman et al. 1981), and GABA (Sherman
and Petty 1981). Alterations in all of these neurotransmitters
have been proposed to be important in the production of inescapa-
ble shock-induced deficits.
CONTROLLABILITY OF SHOCK AND NONOPIOID/OPIOID STRESS-INDUCED
ANALGESIA
Recently, much interest has focused on the reduction in pain
responsiveness following exposure to noxious environmental stimuli
such as electric shock, cold water swim, and restraint. This
phenomenon has been termed stress-induced analgesia (SIA) and has
been reviewed previously (Amir et al. 1980; Bodnar et al. 1980;
Chance 1980; Watkins and Mayer 1982). SIA has been demonstrated
to be either nonopioid or opioid in nature. For example, under
certain circumstances, the analgesic reaction that followed stress
was reversed by opiate antagonists (Amir and Amit 1978; Chesher
and Chan 1977) and was cross-tolerant with morphine (Chesher and
Chan 1977), while in other situations reversal by opiate antago-
nists and cross-tolerance with morphine did not occur (Bodnar et
al. 1978; Hayes et al. 1978). These different reports of opioid
vs. nonopioid SIA suggested that both opioid and nonopioid systems
were involved in mediating SIA, with some aspect of the stressor
determining which form occurred (Grau et al. 1981; Lewis et al.
1980; Maier et al. 1982; Lewis et al. 1981).
Critical factors modulating the appearance of either opioid or
nonopioid SIA have included continuity vs. intermittency of stress
(Lewis et al. 1980), intensity of the stressor (Terman and
Liebeskind 1983), type of stressor (Bodnar et al. 1978), and part
of the body shocked (Watkins et al. 1984). Also, the controlla-
bility/uncontrollability of the stressor has been shown to be a
critical factor in determining the form of SIA observed following
a stressor. Both escapable and inescapable shock led to SIA
shortly following exposure to stress, but only the SIA resulting
from inescapable shock was sensitive to blockade by opiate antago-
nists (Hyson et al. 1982). Furthermore, a brief exposure to
shock, itself insufficient to produce SIA, resulted in an analge-
sic reaction in subjects given inescapable shock 24 hours earlier
(Jackson et al. 1979). It appears that the subjects remained in a
"sensitized state" for at least 24 hours following uncontrollable
stress. Equal amounts of controllable or escapable shock did not
lead to such a reinstatable analgesia (Jackson et al. 1979).
Significantly, this reinstated analgesic reaction produced by in-
escapable but not escapable shock was completely blocked by opiate
antagonists (Maier et al. 1980) and was cross-tolerant with mor-
phine (Drugan et al. 1981).
Due to the differential effects of escapable vs. inescapable shock
on long-term SIA, an important question is whether any differences
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in pain responsiveness occur during the initial exposure to the
stressor in the two groups. Drugan et al. (1985c) observed the
analgesic time course during either 80 escapable or inescapable
shocks of identical intensity and duration (figure 1).
FIGURE 1. Mean tail-flick latency for subjects receiving either
saline or naltrexone (14 mg/kg) 30 minutes prior to
80 escapable or inescapable shocks
Inescapably shocked subjects showed a "double peak" pattern of
analgesia, confirming the prior findings of Grau et al. (1981).
Escapably shocked subjects also exhibited this biphasic pattern of
antinociception after 20 and 80 shocks. However, pretreatment
with the opiate antagonist, naltrexone, completely blocked the
inescapably shock-induced analgesia at 80 shocks, while leaving
the escape analgesia completely intact. Thus, escapable and
inescapable shock exposure resulted in an early nonopioid analge-
sia following 20 shocks which dissipated rather quickly and was
subsequently observed as either a nonopioid or opioid analgesia at
80 shocks for escapably or inescapably shocked subjects respec-
tively.
Until recently, the time course of the analgesia following escap-
able and inescapable shock had not been studied extensively.
Maier et al. (1982) demonstrated that at 30 minutes postshock the
escapable shock analgesia returned to control levels, while the
inescapable shock analgesia was still present. A more detailed
time course of analgesia has since been conducted by Drugan et al.
(1985c). Following 80 shocks, the subjects receiving escapable
shock showed a very transient analgesia which returned to preshock
baseline levels after 10 to 20 minutes, while subjects receiving
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inescapable shock remained analgesic for at least 2 hours
(figure 2).
FIGURE 2. Mean tail-flick latency following 80 escapable or
yoked-inescapable shocks
Thus, the type (opioid vs. nonopioid) and longevity of the
analgesic response to shock was markedly different depending on
the animal's control over the stressor.
The fact that inescapable shock resulted in an opioid form of SIA
and enhanced analgesic responsiveness to systemic morphine (Grau
et al. 1981) suggested the possibility that this sort of stress
might affect other characteristics of opioid activity, especially
dependence. Of particular relevance is the fact that opiate
receptor stimulation resulted in dependence. This dependence
occurred if the opiates were endogenous or systemically adminis-
tered (Miglecz et al. 1979). Withdrawal symptoms were evident
with time elapsed since administration of synthetic opiates or
upon challenge by an opiate antagonist. This phenomenon occurred
after acute or chronic opiate exposure (Wei 1981; Wei and Loh
1976). Therefore, inescapable but not escapable shock might be
expected to exacerbate withdrawal reactions in response to a
challenge of an opiate antagonist. Assessment of opiate with-
drawal behavior required an injection of an opiate agonist (i.e.,
morphine) 30 minutes prior to a challenge by naloxone (Brase et
al. 1976). Naloxone by itself did not lead to behaviors indica-
tive of withdrawal. Moreover, earlier exposure to morphine aug-
mented the degree of withdrawal observed, an effect indicating
that a single morphine injection followed by naloxone challenge
was sensitive to earlier opiate stimulation.
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The above procedure for precipitating withdrawal has proven to be
ideal for assessing whether prior inescapable shock facilitates
withdrawal behavior, possibly because the stress leads to endog-
enous opioid stimulation. We examined whether prior stress
influences precipitated morphine withdrawal and whether the con-
trollability of shock is an important modulating factor (Williams,
Drugan, and Maier 1984). Subjects received 2 sessions of 80
escapable or inescapable shocks or restraint (no shock) separated
by a 24-hour period. Twenty-four hours following the second day
of pretreatment , all subjects received a subcutaneous injection of
morphine sulfate (5 mg/kg). After 30 minutes, subjects were
injected intraperitoneally with naloxone HCL (5 mg/kg); withdrawal
observations began 3 minutes later. The results of this
experiment are represented in figure 3.
FIGURE 3. Mean frequency counts of three withdrawal measures for
subjects given a SC injection of morphine (5 mg/kg)
followed by a naloxone challenge 30 minutes later
NOTE: Withdrawal testing was conducted 24 hours after two daily sessions of
escapable shock, yoked-inescapable shock, or restraint (no shock).
As can be seen, the inescapable shock group displayed a signifi-
cant potentiatfon of morphine withdrawal. Conversely, subjects
receiving the identical amount of escapable shock did not exhibit
any increase in withdrawal behavior in comparison to nonshock con-
trols. On this index of opiate withdrawal, the inescapably
shocked subjects demonstrated previous opioid stimulation, whereas
the escapably shocked subjects did not. Naltrexone administration
prior to shock was conducted in order to insure that this enhanced
withdrawal response of inescapably shocked subjects was due spe-
cifically to previous opioid stimulation. Figure 4 demonstrates
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that the enhanced precipitated opiate withdrawal response can be
blocked by prior administration of the opiate antagonist,
naltrexone.
FIGURE 4. Mean frequency Counts of three withdrawal measures for
subjects given an injection of morphine followed by a
naloxone challenge 24 hours after two sessions of
escapable shock, yoked-inescapable shook, or
restraint
NOTE: Prior to both of the pretreatment sessions. subjects were injected with
either saline or naltrexone (14 mg/kg).
The dissociation of nonopioid/opioid activity in controllably vs.
uncontrollably shocked subjects is quite puzzling from a mecha-
nistic point of view. Are the two analgesic systems aroused by
the different stress experiences separate and unrelated, or does
control over shock engage a system which opposes or suppresses the
activity of endogenous opioid processes? One way to answer such a
question would be to see if prior exposure to escapable or con-
trollable shock would block the appearance of opioid SIA following
a session of inescapable shock. These behavioral "imnunization"
studies have been conducted, showing that prior experience with
controllable shock blocks both short- and long-term opioid analge-
sia observed following inescapable shock (Moye et al. 1981; Moye
et al. 1983). Moreover, a more recent study (Drugan et al.,
1985c) has shown that prior experience with a longer session of
either escapable or inescapable shocks (80 shocks) has very pro-
found effects on a subject's analgesic responsiveness to a session
of 80 inescapable shocks 24 hours later (figure 5).
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FIGURE 5. Mean tail-flick latency during 80 inescapable shocks 24
hours following a session of either escapable or
inescapable shock
NOTE: Thirty minutes prior to the inescapable shock on day 2, subjects received
an injection of either saline or naltrexone (14 mg/kg).
As can be seen in figure 5, prior experience with controllable or
escapable shock resulted in a brief, nonopioid analgesia after 5
and 20 shocks, which rapidly dissipated to control levels; the
typically observed opioid analgesia at 80 shocks is completely
abolished. However, prior exposure to uncontrollable or inescap-
able shock hastened the arrival of opioid SIA on the second day of
inescapable shock exposure. Instead of being observed at 80
shocks, the opioid SIA was now present at 40 shocks. Thus, prior
experience with controllable shock blocked, while prior uncontrol-
lable shock hastened, the expression of opioid SIA. It appears
that control over shock engaged an active process that opposed the
activation of endogenous opioid processes in response to inescap-
able shock.
A POSSIBLE MECHANISM FOR THE PROTECTIVE EFFECTS OF CONTROL OVER
SHOCK
What mechanism might be responsible for the protective effects of
"coping" or control over shock? As previously mentioned, this
protective effect of control is observed on SIA as well as many
other stress pathologies. Interestingly, control over shock and
treatment with benzodiazepines prior to uncontrollable stress both
prevent many of the same stress-related effects. For example,
benzodiazepines selectively inhibited the increase in plasma
corticosterone resulting from inescapable stress (LeFur et al.
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1979). Similarly, controllable or escapable shock induced a much
more transient rise in plasma corticosterone levels, in comparison
to inescapably shocked subjects (Swenson and Vogel 1983). Benzo-
diazepines reduced gastric ulcers induced in rats by stress (File
and Pearce 1981), whereas stress-induced ulceration was observed
following inescapable but not escapable shock (Weiss 1971).
Benzodiazepines produced a significant attenuation of morphine-
induced analgesia when injected intracerebroventricularly (ICV) or
into the periacqueductal gray (PAG) simultaneously with a sub-
cutaneous injection of morphine (Mantegazza et al. 1982), while
escapable shock given prior to inescapable shock blocked both
short- and long-term opioid SIA (Drugan et al. 1985c; Moye et al.
1981; Moye et al. 1983).
The similarities between control over shock and benzodiazepine
administration prior to inescapable stress suggested the possibil-
ity that anxiety or fear may be a critical factor in the produc-
tion or prevention of stress-induced opioid analgesia and other
stress pathologies. In fact, behavioral studies investigating the
relationship between fear and antinociception supported this con-
tention. Specifically, although unconditioned analgesia induced
by a stressor is sometimes opioid and sometimes not, conditioned
analgesia appears to be opioid in nature (Sherman et al. 1984;
Watkins and Mayer 1982). In support of this idea is the finding
that conditioned analgesia was reversible by opiate antagonists
(Watkins and Mayer 1982). Finally, the analgesia elicited by cues
that have been paired with a stressor has been opioid in nature
even if the stressor itself led to a nonopioid analgesia (Watkins
and Mayer 1982).
If the opioid SIA observed following inescapable shock is in some
fashion a result of anxiety or fear, then an antianxiety compound
should block or attenuate this effect. Chlordiazepoxide (Librium)
is a classic 1,4 benzodiazepine which is known to have potent
anxiolytic action in both animals and man. However, it is impor-
tant to tolerate out the side effects of muscle relaxation and
sedation to ensure that the effects of the compound are due to its
anxiolytic action. Therefore, prior to experimentation, all sub-
jects were given one injection of 10 mg/kg chlordiazepoxide (CDP)
per day for 4 days, to tolerate out the sedative effects. Then,
on day 5, half of the subjects received an IP injection of 5 mg/kg
CDP, while the remainder of the subjects received distilled water
30 minutes prior to a session of inescapable shock. Twenty-four
hours later and 30 minutes prior to reinstating shocks and subse-
quent analgesia testing, subjects received an IP injection of
either CDP or saline (Drugan et al. 1984). Figure 6 demonstrates
the impact of a benzodiazepine on the inescapable shock-induced
long-term opioid analgesia.
As can be seen in the figure, CDP given prior to inescapable shock
completely blocked the long-term opioid analgesia. It is impor-
tant to note that benzodiazepine administration prior to test on
day 2 had no effect. It appears that the initiation of anxiety or
fear resulting from the session of inescapable shock set into
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motion some sort of
responsible for the
other deficits.
process (transmitter depletion?) that is
expression of the opioid SIA, and possibly for
FIGURE 6. Mean tail-flick latency 24 hours following 80
inescapable shocks
NOTE: Thirty minutes prior to inescapable shock and tall-flick testing, subjects
were given an injection of either distiIled water or chlordiazepoxide
(Librium, 5 mg/kg).
Control over shock protects the subject from many of the deleteri-
ous effects of inescapable shock in a similar fashion to the
benzodiazepines. Does control over shock act in the same way as
the pharmacological pretreatment of benzodiazepines prior to
stress? The benzodiazepine receptor appears to be functionally
coupled to both a gamma-aminobutyric acid (GABA) receptor and an
associated chloride ionophore (Paul et al. 1981). It has been
demonstrated that benzodiazepines increase GABA binding and can
facilitate GABAergic transmission (Biggio et al. 1977; Costa et
al. 1978). It is believed that benzodiazepines do not mimic GABA
but instead facilitate GABAergic transmission by sensitizing GABA
receptors to the natural agonist (Costa et al. 1976). Finally, it
has been proposed that it is the GABAergic system that mediates
the anxiolytic action of the benzodiazepines (Costa et al. 1976).
In support of this notion, GABA-mimetic drugs (e.g., valproic
acid) have anxiolytic activity comparable to diazepam in two types
of animal tests known to predict the anxiolytic action of drugs
(Lal et al. 1980). Hence, if control over shock is working in a
similar fashion to the benzodiazepines, then it should result in a
facilitation of GABAergic transmission as well. This increase in
GABAergic transmission would be reflected in greater GABA effec-
tiveness and/or greater inhibition in the central nervous system
(CNS). A technique that gave an index of central GABAergic
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processes would be informative in evaluating whether or not
control over shock augments GABAergic transmission.
The classic benzodiazepines (i.e., diazepam and chlordiazepoxide)
have anticonvulsant properties as well as anxiolytic actions. It
is believed that the anticonvulsant action of these drugs is due
to their action on the GABAergic system (Schmutz 1983). Drugs
such as bicuculline or picrotoxin, which antagonize GABAergic
transmission, are known to act as convulsive agents. In fact,
GABA-antagonist induced seizures have been used as a behavioral
index of the activity level of central GABAergic processes
(Soubrie et al. 1980).
Drugan et al. (1985b) used bicuculllne-induced seizures in sub-
jects that received escapable shock, inescapable shock, or no
shock to assess the impact of controllability of stress on
GABAergic tone. Two hours poststress was used as the time point
for the precipitation of seizures for several reasons. There is a
dissociation between escapably and inescapably shocked subjects on
behavioral (Glazer and Weiss 1976), plasma corticosteroid (Swenson
and Vogel 1983). and analgesic (Drugan et al., 1985c) indices at
this time. The latencies to myoclonus (neck jerk) and clonus
(loss of posture) were chosen as dependent variables as these have
been used by other researchers in the field (Adler 1969; Greer and
Alpern 1977). Figure 7 shows the latency to myoclonus and clonus
for all groups given an IP injection of either 4, 6, or 8 mg/kg
bicuculline 2 hours postshock.
Interestingly, both control and lack of control over shock dramat-
ically altered the subjects' susceptibility to bicuculline-induced
seizure in comparison to nonshocked controls. Escapable shock
protected against seizures, while inescapable shock facilitated
seizures. In addition, at the effective dose (6 mg/kg), control
over shock protected against the lethal effects of these chemi-
cally-induced seizures, in comparison to all other groups. More
specifically, following the 6 mg/kg challenge of bicuculline, 31
percent of the escapably shocked subjects, 69 percent of the in-
escapably shocked subjects, 69 percent of the restrained subjects,
and 63 percent of the naive subjects died following seizures.
Thus, not only did control over shock delay the onset of bicu-
culline-induced seizures. it also protected against the lethal
effects.
CONTROLLABILITY AND GABAERGIC TRANSMISSION: A THEORETICAL MODEL
In sum, it appears that experience with controllable vs. un-
controllable aversive events such as electric shock markedly
influence the organism's reaction to the stressor. Exposure to
uncontrollable shock leads to a variety of pathologies including
opioid stress-induced analgesia. Conversely, exposure to control-
lable shock results in few if any stress effects and a transient
nonopioid stress-induced analgesia. The data presented in this
paper suggest that anxiety and fear may play a major role in pre-
cipitating many of the stress pathologies and opioid SIA reported.
80
Since GABA is such a ubiquitous neurotransmitter in the brain,
having interactions with many stress- and anxiety-related systems,
a theoretical model is proposed to account for the effects of
FIGURE 7. Mean latency to the onset of myoclonic and clonic
convulsion following an IP injection of either 4, 6,
or 8 mg/kg bicuculline 2 hours following escapable
shock, inescapabte shock, restraint, or no treatment
(naive)
NOTE: Vertical bars represent standard errors.
control/lack of control over shock with GABA as the critical link.
Figure 8 (Drugan 1984) shows that GABA tonically inhibits many
systems thought to be critical in the expression of opioid SIA
(hypothalamopituitary adrenal axis) and anxiety (e.g., GABA
itself, norepinephrine, and serotonin).
Thus, facilitation or interference with GABAergic transmission is
hypothesized to have a profound effect on other critical systems.
For example, if control over shock results in GABAergic facili-
tation, then this should result in an inhibition of the release of
corticotropin-releasing factor from the hypothalamus, which would
mobilize the hypothalamopituitary adrenal (HPA) axis (Buckingham
1980). Conversely, if lack of control results in an interference
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with GABA, then a release of inhibition of the HPA axis would
ensue, with release of pituitaryß-endorphin and opioid SIA. In
support of this notion, both basal and stress-induced activity of
the HPA axis in the rat were found to be reduced when GABA was
implanted into the third ventricle and were enhanced by the injec-
tion of the GABA-receptor antagonists, picrotoxin and bicuculline
(Makara and Starr 1974). This relationship between GABA and the
HPA axis is important because the pituitary-adrenal axis has been
demonstrated to be involved in the long-term opfoid SIA following
inescapable shock. Specifically, either hypophysectomy, adrenal-
ectomy. or dexamethasone will completely block the inescapable
shock-induced opioid SIA (MacLennan et al. 1982).
FIGURE 8. A theoretical model which suggests that the differ-
ential impact of escapable vs. inescapable shock is
due to their respective effects on the GABAergic
system. This differential impact is proposed to
alter many important stress-related systems.
Another relevant interaction of GABA processes is its relationship
with other neurotransmitter systems thought to be involved in
anxiety-related behaviors. For example, pharmacologically in-
creasing serotonin levels increases anxiety-related behaviors in
rats (Iverson 1983). Thus, augmenting serotonergic activity has
anxiety-inducing effects. Interestingly, it has been shown that
GABAergic neurons terminate on , and exhibit an inhibitory influ-
ence on, the raphe nucleus (Gallager 1978), the originating
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nucleus for the ascending serotonergic (5-HT) tract, which
innervates certain components of the limbfc system thought to be
critical in anxiety (i.e., amygdala and hippocampus). Thus,
GABAergic facilitation, as observed in subjects able to control
shock, might be expected to have anxiolytic effects due to
inhibition of the ascending 5-HT system. Conversely, subjects
unable to control shock, resulting in interference with GABAergic
processes, would be expected to have anxiogenic effects resulting
from disfnhibition of this system.
Redmond and Huang (1979) have proposed that the dorsal noradre-
nergic bundle is important in the production of anxiety. Drugs
that are known to reduce the activity of the locus coeruleus (the
originating nucleus of the dorsal noradrenergic bundle), such as
benzodiazepines, have anxiolytic actions. However, drugs that
increase locus coeruleus activity cause anxiety in animals and
man, as does electrical stimulation of this area (Redmond et al.
1977). Significantly, GABAergic neurons terminate on, and exert
an inhibitory influence on, the locus coeruleus neurons (Iverson
1983). Thus, control over shock, resulting in GABAergic facili-
tation, might be expected to have anxiolytic action in this system
as well, due to inhfbition of locus coeruleus neurons. Finally,
inescapably shocked subjects would have an active ascending
noradrenergic (NE) system due to disinhfbition of GABA on locus
coeruleus neurons, which would result in anxiety.
PURPOSE OF MODEL
This theoretical model was not conceptualized to answer all the
questions about controllability and stress effects. Rather, it
has been proposed in an effort to provide a certain perspective on
how "coping" or control over stress might have protective effects.
It is hoped that this model will guide subsequent research on
subjects able to control stress, rather than examining merely
those unable to control. Our feeling is that the mechanism or
process modulating the protective effects of control over stress,
once understood and characterized, will result in better fine-
tuning of pharmacotherapy in many stress-related disorders in
humans.
RELEVANCE TO DRUG ABUSE
At first blush, the data presented in this paper may not seem
directly relevant to the study of drug addiction. However, care-
ful reconsideration will reveal that the dimension of control-
lability over a stressful event, or anxiety/fear, modulates the
activity of endogenous opiofds as evidenced by opioid SIA and
potentfated morphine withdrawal. In addition, this activation of
opiofd systems renders the subject more sensitive to the analgesic
effects of systemically administered morphine (Grau et al. 1981).
Since the previously mentioned opioid SIA is blocked by pretreat-
ment with a benzodiazepine, anxiety or fear appears to be an
important precipitating factor. Thus, learned helplessness has
been conceptualized as being an animal model for anxiety-mediated
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depression (Drugan et al. 1985a). Since addicts tend to score in
the mild-moderate range of depression (Craig, this volume), this
model may shed some light on the etiology of addictive behavior in
humans.
In a clinical setting, people who have experienced uncontrollabil-
ity of life events, have chronic anxiety, or possess an external
locus of control may be candidates for drug abuse for several
reasons. First, as mentioned above, either uncontrollable aver-
sive events or anxiety/fear result in activation of endogenous
opioid systems. This "primed" opioid system may alter the indi-
vidual's first reaction(s) to an opiate (e.g., greater euphoria)
in comparison to those of other people. This different action of
the opiate may precipitate or hasten the addiction process. In
addition, these individuals may be more likely to experiment with
drugs as a "coping" mechanism in order to combat their emotional
predicament. Thus, this "coping through drug use" and the differ-
ential reaction to opiates themselves could be the mechanism
responsible for the acquisition and maintenance of drug abuse.
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Behavioral Contingencies Involved
in Drug-Induced Neurotransmitter
Turnover Changes
Steven I. Dworkin and James E. Smith
INTRODUCTION
Recent advances in techniques used to investigate the neuroanatom-
ical, neurophysiological, and neurochemical mechanisms of action
of psychoactive drugs have been substantial. Neuroscientists have
not only determined the chemical and physiological effects of
these drugs, but also, in some cases, the anatomical locus where
these effects are exerted. Investigations of the parameters of
opiate action exemplify how these neurobiological techniques have
increased understanding of the mechanisms of action of substances
that affect behavior. Receptor-binding and autoradiographic dis-
tribution studies have shown the complex behavioral effects of
opiates to be produced by actions at specific recognition sites in
the central nervous system. These techniques have also assisted
in the detection and characterization of endogenous substances
that interact with these receptors to produce effects that opiates
appear to mimic. However, irrespective of how sophisticated
neurobiological techniques for investigating the direct actions of
drugs become, understanding the basic mechanisms responsible for
substance abuse will likely not be possible unless these phenomena
are studied in the context of behavioral and environmental varia-
bles that result in and from drug self-administration.
CHARACTERISTICS OF SUBSTANCE ABUSE
One necessary component of substance abuse is behavioral--the use
or self-administration of the particular substance. Acknowledging
this component places appropriate emphasis on the importance of an
experimental analysis of the behavioral components of self-
administration, while not suggesting that physiological or neuro-
biological aspects are unimportant. Investigations of the neuro-
biological consequences of the administration of substances to
biological preparations can provide information concerning the
necessary conditions for abuse potential. Aside from occasional
self-administration of an inappropriate drug or dose regimen
(e.g., taking an antibiotic for a cold), there may be some common
neurobiological mechanism of action of substances. This mechanism
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has been proposed by some to be an action on the mesolimbic-
mesocortical dopamine system (Wise and Bozarth 1981) or on the
noradrenergic-endorphinergic system (Belluzzi and Stein 1977).
Many substances with abuse liability have several characteristic
behavioral effects in common. These agents have response-rate-
altering properties that result in modifications of ongoing levels
of activity, and stimulus properties that permit humans and non-
humans to detect their administration. These substances also have
reinforcing properties that result in their ability to maintain
high rates and extended sequences of behavior. However, these
properties are not invariant and are subject to modification by
pharmacological, neurobiological, and behavioral variables
(Barrett and Katz 1981; Barrett and Witkin, in press). Psycho-
active substances are not qualitatively different from other
environmental stimuli that exert control over behavior. Research
into the control of behavior by consequent events (operant condi-
tioning) has been beneficial in understanding the behavioral
parameters of substance abuse.
The dynamic properties of reinforcers are often overlooked. The
same electric shock can serve as a punisher and suppress behavior,
a negative reinforcer increasing behavior that results in its
termination, and a positive reinforcer maintaining behavior that
results in its presentation, even with the same animal (figure 1).
Squirrel monkeys initially trained to postpone electric shocks
(negative reinforcement) continue to respond when the same inten-
sity shock is made contingent on responding (positive reinforce-
ment). This responding is directly related to shock intensity
with higher intensity maintaining higher response rates. Respond-
ing extinguishes when shock is eliminated and occurs again when
shock is reintroduced. Electric shock can suppress food-main-
tained responding (punishment) and maintain responding that
results in its presentation (positive reinforcement) in different
components of a multiple schedule (Morse et al. 1977; Barrett and
Katz 1981). The importance of the precise contingencies between
responding and shock presentation is indicated by the demonstra-
tion that shock can reinforce behavior when delivered under an
interval schedule but punish behavior when delivered under a ratio
schedule (Branch and Dworkin 1981).
Similar results have been seen with psychoactive substances.
Cocaine (figure 2) and nicotine (figure 3) can be both positive
and negative reinforcers in the same animal (Spealman 1985).
Moreover, nalorphine (a mixed opiate agonist-antagonist) produces
severe withdrawal when administered to an opiate-dependent animal,
but can also serve as a reinforcer to opiate-dependent monkeys
(Goldberg et al. 1971) (figure 4). These and similar findings
demonstrate that behavioral history, particularly the different
types of contingent relationships between behavior and the deliv-
ery of an environmental event , can alter the punishing or re-
inforcing efficacy of that event.
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FIGURE 1. Development of the positive reinforcing effects of
response-produced electric shock presesentation to
squirrel monkeys
NOTE: Responding was initially maintained by a Sidman Avoidance schedule where
responding postponed shock presentations (upper panels). A conjoint fixed-
interval 5-minute schedule of shock presentation was then added to the
postponemant schedule. Most responses continued to postpone shocks.
However, responses produced shocks on a fixed-interval 5-minute schedule.
When the postponement schedule was eliminated, responding was maintained by
the fixed-interval schedule of shock delivery (third panel). The addition
of a conjoint ratio schedule of response-produced shock eventually elimi-
nated responding by monkey 525. A behavioral history of different contin-
gencies between responding and the delivery of electric shock altered the
reinforcing nature of shock, changing It from a negative reinforcer to a
positive reinforcer to a punisher. (Branch and Dworkin 1981.)
Copyright 1981, Society for the Experimental Analysis of Behavior, Inc.
IMPORTANCE OF CONTINGENCIES
Substances that have profound pharmacological and behavioral
effects should not be considered reinforcing until contingent or
contiguous relationships between behavior and administration are
evaluated. When it has been demonstrated that the behavior that
precedes administration is increased in frequency and that the
drug has not directly elicited the behavior, then the substance
can be considered reinforcing. Reinforcement cannot be assumed in
the absence of contingent or contiguous relationships (Skinner
1938).
The effects of noxious stimuli have also demonstrated the impor-
tance of behavioral variables. Although the noncontingent pres-
entation of noxious stimuli have been shown to produce many
behavioral and physiological changes, other factors have been
implicated in stress-related diseases (Weiss et al. 1981). A
stress-inducing environment contains at least three components:
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FIGURE 2. Development of the positive reinforcing effects of
NOTE:
nicotine
Responding was engendered and subsequently maintained by a nicotine
postponemant procedure. In the absence of responding, nicotine injections
were delivered (first panel). A fixed-interval schedule of nicotine
injections was superimposed on the postponement schedule (second panel).
After the postponement contingency was eliminated, responding was main-
tained by the fixed-interval schedule alone (bottom two panels). The
behavioral history of the different response contingencies changed the
effects of nicotine from a negative reinforcer to a positive reinforcer.
(Spealman 1985.) Copyright 1985, Alan R. Liss Company.
(1) a noxious stimulus (usually electric shock); (2) stimuli that
are paired with the presence or absence of a pending noxious stim-
ulus (predictability); and (3) a coping response that results in
the postponement or termination of the noxious stimulus (control).
Several studies have shown that the second two components, consid-
ered to be "psychological," can modulate the behavioral, physio-
logical, and neurochemical effects of noxious stimulation (Badia
and Culbertson 1972; Seligman and Maier 1967). Procedures used on
rhesus monkeys to assess simultaneously the effects of noxious
stimulation that could or could not postpone electric shocks have
demonstrated the importance of response contingencies (Brady et
al. 1958). One monkey received a shock every 20 seconds unless a
bar-press response was emitted, which delayed the shock for 20
seconds. A second monkey was yoked to the shock schedule of the
responding monkey but had no opportunity to postpone presen-
tations. Thus, the number of shocks delivered to both subjects
was the same, but only one monkey could delay them for himself and
his yoked partner. This avoiding animal (with control) developed
extensive gastrointestinal lesions. Opposite effects were ob-
served when rats were used in a systematic replication and exten-
sion of this study (Weiss 1968; Weiss 1971). Yoked rats (without
control) developed more and larger gastrointestinal lesions
compared to subjects that could delay shocks. It was suggested
that the major factor responsible for the differences observed
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FIGURE 3. Development of responding simultaneously maintained by
a variable-interval schedule of IV cocaine injection
and a fixed-interval schedule of termination (time-
out from cocaine injections)
NOTE: First panel shows responding maintained by a variable-interval contingency.
Responding on a single lever produced an IV cocaine infusion at variable
Intervals averaging 3 minutes. Subsequent panels show responding main-
tained by two concurrently scheduled contingencies. Responding on one
lever continued to produce cocaine injections under the variable-interval
schedule. Responses on a second lever were maintained by a fired-interval
5-minute termination schedule. Responses on this lever after a 3-minute
fixed Interval of time elapsed terminated the schedule of cocaine injec-
tions for a 1-minute time-out period. Thus, responding was simultaneously
maintained bv cocaine injections (positive reinforcement) and a time-out
from the opportunity to receive additional cocaine infusions (negative
reinforcement). (Spealman 1985.) Copyright 1985, Alan R. Liss Company.
between the two studies was the difference in response rates of
the shock-postponing animals (Weiss 1971; Weiss 1972). In the
first study, monkeys with the highest rates of responding were
designated as the avoiding subjects, while a random assignment
procedure was used in the rat study. Additional research sup-
ported the suggestion that response rates were important in
stress-induced physiological changes (Weiss 1968). Animals with
the opportunity to postpone electric shock presentation have
increased levels of brain neurotransmitters compared to yoked-
shock animals. Increases in norepinephrine, dopamine, and
serotonin were seen in the hypothalamus, anterior cortex, and
brain stem, respectively (Weiss et al. 1981). The ability to
control or predict the occurrence of noxious stimuli has consider-
able behavioral, physiological, and neuropharmacological effects.
It is not surprising that similar control over, or predictability
of, other environmental stimuli also have profound neurobiological
influences.
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FIGURE 4. Demonstration of the reinforcing effects of nalorphine
delivered to a morphine-dependent monkey
NOTE: Various doses of nalorphine substituted for contingent morphine injections
over a 7 1/2-hour period and maintained higher rates of responding than
either morphlne (points above "C" and broken horizontal Iine) or saline
(points above "s"). (Goldberg et al. 1971.) Copyright 1971,
American Society for Pharmacology and Experimental Therapeutics.
NEUROBIOLOGICAL CONSEQUENCES OF REINFORCER PRESENTATION
The behavioral consequences of reinforcer presentation are thought
to result from, and in, changes in neuronal transmission in the
central nervous system. Reinforcer presentatfon likely initiates
neuronal activity in pathways that mediate and may be "dedicated"
to these processes (demonstrated by intracranial electrical self-
stimulation). Thus, the neuronal events resulting from reinforce-
ment are the neurobiological substrates of these phenomena. The
elucidation of these substrates would include the identification
of the neuronal circuits that mediate these processes (figure 5).
The identification of each component neuron and the receptors in-
volved in the neuronal circuit would be necessary to such elucida-
tion as would knowledge of the influence of other inputs. Such
information is not yet available for even the most simple
behavior. However, recent methodological developments such as
multiple neurotransmi tter turnover rates, 2-deoxyglucose auto-
radiography, and neurotransmitter receptor imaging will likely
permit significant new advancements.
NEUROBIOLOGICAL SUBSTRATES OF CONTINGENT REINFORCER PRESENTATION
The contingent presentation of an event that increases the
probability of the response that preceded its presentation is a
reinforcer. The noncontingent presentation of the identical
potentially reinforcing stimulus does not appear to have the same
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Neurobiological Mechanisms
FIGURE 5. Neurobiological mechanisms
NOTE: The neurobiological substrates of a behavior would include knowledge of:
(a) the neuronal circuits and pathways that mediate the behavior with
identification of each component neuron and the neurotransmitters released
by each; (b) characterization of end localization of the neurohumoral
receptors involved; and (c) the role of other Inputs to each participating
neuron.
properties. As previously discussed, response-contingent presen-
tation is necessary for an event to establish reinforcing proper-
ties, while response-independent presentation to the same organism
cannot be considered a reinforcer and may even be an aversive
stimulus. Rats that have produced response-dependent presentation
of electrical stimulation to a brain region will respond to termi-
nate the same stimulation-delivered response independently on an
identical schedule (Steiner et al. 1969). Drugs with reinforcing
properties seem to have similar effects. Monkeys intravenously
self-administering cocaine will respond to terminate the opportu-
nity to receive additional periodic cocaine infusions (Spealman
1985). These data suggest that the response-independent presenta-
tion of a potentially reinforcing stimulus is not a reinforcer to
organisms that have previously exercised control over its presen-
tation. Moreover, the reinforcing nature of a stimulus can be
changed by alterations in the contingencies under which it is
presently removed.
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NEUROBIOLOGICAL SUBSTRATES OF CONTINGENT DRUG PRESENTATION
Neuropharmacologic and behavioral pharmacologic data suggest that
the contingent presentation of drugs is clearly different from
noncontingent presentation. These differences must result from,
and in, differences in neuronal activity between the two condi-
tions. These differences may represent reinforcing neuronal
activity and the neuronal processes associated with contingent
presentation that are directly related to reinforcement. Inves-
tigation of the neurobiological differences between intravenous
opiate self-administration and yoked-passive morphine or yoked-
vehicle infusion have suggested the involvement of specific neu-
ronal systems in these processes (Smith et al. 1982; Smith et al.
1984a; Smith et al. 1984b).
Neurotransmitter Turnover Rates
Triads of male littermate rats were surgically prepared with
chronic jugular catheters and two of the littermates made physi-
cally dependent on morphine sulfate with hourly infusions of
increasing dosages (3 days each of 1.25, 2.5. 5.0 mg/kg/infusion
and 2 days of 10.0 mg/kg/infusion), while the third littermate re-
ceived hourly vehicle infusions. One of the physically dependent
rats was then allowed to self-administer morphine intravenously
(10 mg/kg/infusion) with 24-hour access on a fixed-ratio schedule
increased from 1 to 10 during the first week. The other physical-
ly dependent littermate received identical yoked infusions of
morphine, while the third littermate continued to receive yoked
infusions of vehicle. When self-administration stabilized (3 to 4
weeks), each littermate was pulse labelled with radioactive pre-
cursors to the biogenic amine (0.5 mCi 3Hitryptophan and 1.0 mCi
H-tyrosine) and the amino acid (0.2 mCi 14C-glucose) neuro-
transmitters. Groups of litters were sacrificed by immersion in
liquid nitrogen after either 60 (n=5) or 90 minutes (n=6), at a
time when each self-administering animal was most likely to take
another self-infusion (calculated from self-administration inter-
vals for the previous 72 hours). The brains were removed at
-20 °C, cut into 1 mm coronal sections, and dissected into 11
brain regions at -20 °C. Each brain region was pulverized in
liquid nitrogen and a portion of tissue taken for the extraction
and assay of the content and specific radioactivity of the bio-
genic amine neurotransmitters; another portion was taken for the
same determinations of the amino acid neurotransmitters. The
half-life was determined for each from a semilogarithmic plot of
the specific radioactivities at the two time points, and rate
constants and turnover rates were calculated (Smith et al. 1982).
Biogenic Monoamine Turnover Rate Changes
Passive morphine infusion (yoked-morphine vs. yoked-vehicle) re-
sulted in fewer and generally smaller significant changes in dopa-
mine (DA), norepinephrine (NE), and serotonin (5-HT) turnover than
did the contingent administration (self-administering animals vs.
yoked-morphine infused) (figure 6). Four significant changes
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FIGURE 6. The effects of noncontingent passive intravenous
morphine infusion determined by comparing yoked-
morphine and yoked-vehicle infused littermates) and
contingent intravenous morphine self-administration
determined by comparing the self-administering
animals with the yoked-morphine infused littermates)
on the turnover rates of dopamine, norepinephrine,
and serotonin in 11 brain regions
NOTE: Values are the percent change of the significant differences.
in turnover occurred in the yoked-morphine infused littermates
compared to the yoked-vehicle infused animals, while seven signif-
icant differences were seen between the self-administering and the
yoked-morphine littermates. The decreases in turnover of NE in
the amygdala and 5-HT in the entorhinal-subicular cortex likely
represent a direct drug effect, since these changes were seen in
both drug groups irrespective of the contingency. The increase in
DA turnover rates in the caudate nucleus-putamen of the yoked-
morphine group was even further increased in the self-administer-
ing group, while the increase in the nucleus accumbens was
reversed to almost no turnover at all in the self-administering
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animals. In one situation, the self-administration contingency
exacerbated a change and in the other, it totally attenuated the
change and resulted in an even greater effect in the opposite
direction. It is interesting to speculate about the underlying
basis of these changes. The differences between the contingent
control of reinforcer presentation and the noncontingent presenta-
tion of a potential reinforcer may not represent simply reinforc-
ing efficacy differences. The potential reinforcer presented
noncontingently may activate some pathways that participate in
reinforcement when the drug is administered response-dependently
(e.g., DA innervations of the caudate nucleus-putamen). Further-
more, noncontingent presentation may have aversive properties
resulting in a reversal and change in the opposite direction to
that of contingent presentation (e.g., DA turnover in the nucleus
accumbens).
Five changes in biogenic monoamine turnover rates appear to be
related to the reinforcing properties of contingent self-admin-
istration. These include increases in DA turnover in the frontal
cortex and septum, the increase in NE turnover in the septum, and
decreases in NE and 5-HT turnover in the nucleus accumbens of the
self-administering animals.
Amino Acid Turnover Rate Changes
The passive noncontingent administration of morphine resulted in
11 significant changes in aspartate (Asp), glutamate (Glu), and
gamma-aminobutyric acid (GABA) turnover, while the contingent
self-administration resulted in 22 changes (figure 7). Four turn-
over rate changes appeared to be direct pharmacological effects of
morphine since they were identical in both drug groups, regardless
of the contingency. These changes included increases in Asp turn-
over in the septum, Glu turnover in the nucleus accumbens and
septum, and in GABA turnover in the entorhinal-subicular cortex.
Five of the other changes in the yoked-morphine group may be
related to the differences between contingent self-administration
and noncontingent administration , since they were nullified and
often significantly changed in the opposite direction in the self-
administering animals. These changes included the decreases in
turnover rates of Asp and Glu in the caudate nucleus-putamen, Asp
in the amygdala, and GABA in the septum, and increases in GABA In
the caudate nucleus-putamen and nucleus accumbens. Two signifi-
cant changes in the yoked-morphine group were even greater in the
self-administering littermates. These changes included the in-
creased turnover rates of GABA in the caudate nucleus-putamen and
hypothalamus.
Of the 22 changes resulting from the contingent self-administra-
tion, 15 appear to be related to the reinforcing properties of
intravenous morphine. These include the increases in Asp turnover
rates in the frontal cortex, hippocampus, thalamus, motor-somato-
sensory cortex, and brain stem; increases in Glu turnover in the
frontal cortex, hippocampus, amygdala, and motor-somatosensory
cortex; and increases in GABA turnover in the frontal cortex,
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hippocampus, amygdala, thalamus, motor-somatosensory cortex, and
brain stem. Six other changes were reversals of the changes seen
in the passive morphine-infused group, which included increases in
turnover rates of Asp in the caudate nucleus-putamen and amygdala,
in Glu in the caudate nucleus-putamen, in GABA turnover in the
septum, and decreases in the nucleus accumbens. The remaining two
changes were even greater increases in turnover of GABA in the
self-administering littermates in the caudate nucleus-putamen and
hypothalamus.
FIGURE 7. The effects of noncontingent passive intravenous mor-
phine infusion and contingent intravenous morphine
self-administration on the turnover rates of aspar-
tate, glutamate, and gamma-aminobutyric acid in 11
brain regions
NOTE: Values are the percent change of the significant differences.
100
Acetylcholine (ACh) Turnover Rate Changes
The turnover rates of ACh were determined in 14 brain regions of
14 additional triads of littermates to assess the role of choli-
nergic neuronal systems in contingent and noncontingent morphine
presentation. Three significant changes in turnover rates were
seen in the yoked-morphine infused group and four were seen in the
self-administering group (figure 8). Two of the three changes in
the yoked-morphine infused littermates appeared to be related to
the direct effects of morphine, since the changes were seen in
both drug groups, regardless of the contingency. These included
the increase in turnover in the diagonal band region and the medi-
al septum. The increase in ACh turnover in the frontal cortex in
the yoked-morphine group was even greater in the self-administer-
ing littermates, while decreases in turnover were seen in the
pyriform cortex, nucleus accumbens, and amygdala of this latter
group.
FIGURE 8. The effects of noncontingent passive intravenous mor-
phine infusion and contingent intravenous morphine
self-administration on the turnover rates of acetyl-
choline in 14 brain regions
NOTE: Values are the percent change of the significant differences.
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Neurotransmitter Receptor Changes Correlated With Contingent and
Noncontingent Presentations of Intravenous Morphine
The tissue remaining from the litters in which ACh turnover rates
were measured was used to determine muscarinic cholinergic- and
benzodiazepine-binding characteristics. Scatchard analysis and
Hill plots demonstrated significant differences in muscarinic
cholinergic-binding between the noncontingent and contingent pres-
entations of morphine (figure 9). Four changes in the yoked-
morphine group appeared to be direct drug effects, since these
FIGURE 9. The effects of noncontingent passive intravenoue
morphine infusion and contingent intravenous morphine
self-administration on the density of binding sites
for 3H-quinuclidinyl bensilate and 3H-flunitrazepam
determined in eight brain regions
NOTE: Values are the percent change in BMax for the significant differences.
were also present in the self-administering animals. These
include the increase in muscarinic cholinergic-binding in the
pyriform cortex and decrease in the cingulate cortex, and the
decrease in benzodiazepine-binding in the hippocampus and ento-
rhinal-subicular cortex. Three significant changes in muscarinic
cholinergic-binding were observed in the self-administering
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animals that appeared to be related to the reinforcing effects of
contingent drug delivery. These included the increase in the
amygdala and the decrease in the frontal cortex and entorhinal-
subicular cortex. The changes in the amygdala and frontal cortex
were the inverse of changes in ACh turnover seen in these areas,
while the changes in binding in the entorhinal-subicular cortex
suggested a net increase in total activity that was not observed
as a turnover rate change. The pulse-labelling intervals for ACh
turnover were 5 and 10 minutes. The turnover-rate measures may
not be representative of the total neuronal activity during the
11O-minute interinjection interval. Accordingly, the increases in
ACh turnover in the frontal cortex of the yoked-morphine group and
in the pyriform cortex and nucleus accumbens of the self-adminis-
tering animals may not represent net changes in neuronal activity,
since no changes in muscarinic cholinergic-binding were observed
in these areas. However, the changes in the frontal cortex and
the amygdala of the self-administering littermates are consistent
with total net changes in activity since inverse changes in
binding were observed.
NEURONAL CIRCUITS MEDIATING THE REINFORCING EFFICACY OF CONTINGENT
MORPHINE PRESENTATION
Integrating these neurochemical data and data from studies of the
effects of pharmacological blockade or neurotoxin lesion on intra-
venous morphine self-administration with knowledge of neurotrans-
mitter-specific neuronal pathways suggests two neuronal circuits
to be involved in the processes maintaining intravenous morphine
self-administration, which include its reinforcing efficacy (Smith
et al. 1984a). A nucleus accumbens-pre-optic nucleus-amygdala-
entorhinal cortex-hippocampus-nucleus accumbens circuit and a
frontal cortex-striatum-frontal cortex circuit were identified
that included ACh, DA, NE, 5-HT, Asp, Glu, and GABA neurons.
Activity in these circuits appears to be modulated by feedforward
pathways from brain stem biogenic monoamine systems, while GABA
feedback pathways from these circuits appear to modulate activity
in these brain stem centers. These circuits may represent general
reinforcement systems and not just opiate reinforcement processes,
since 2-deoxyglucose autoradiography in the brains of animals
intracranially self-stimulating identified many of the same re-
gions as in these intravenous morphine self-administering animals.
OTHER NEUROBIOLOGICAL EVIDENCE FOR DIFFERENCES BETWEEN CONTINGENT
AND NONCONTINGENT PRESENTATION OF REINFORCERS
Responding by rats can be maintained by the termination of elec-
trical stimulation of brain regions where such stimulation was
previously self-administered (Steiner et al. 1968), suggesting the
development of potential aversive properties when control over
presentation is removed. The autoradiographic assessment of the
distribution of 3H-2-deoxyglucose in the brains of animals elec-
trically self-stimulating intracranially, compared to noncontin-
gent presentation to previous self-stimulators, showed increases
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in glucose utilization bilaterally in the medial prefrontal cortex
and ventrolateral thalamus, and ipsilaterally to the stimulating
electrode in the nucleus accumbens (Porrino et al. 1984). These
data suggest that neuronal activity in these regions was increased
in the animals receiving contingent presentation of the electrical
stimulus. However, no significant differences in the noncontin-
gent stimulated group (not seen in the contingent group) that
could be identified as resulting from changes in neuronal activity
potentially correlated with the aversive properties of this loss
of control over a previously contingent reinforcer were seen.
CONCLUSIONS
The noncontingent intravenous presentation of morphine results in
fewer and generally smaller changes in the turnover rates of seven
neurotransmitters and two neurohumor binding sites than does the
contingent presentation of the drug. Response-contingent drug de-
livery has greater effects upon these systems than those effects
observed to be related to the drug itself. These differences
likely result from the reinforcing properties resulting from con-
trol over drug presentation. Behavioral consequences appear to
determine some of the neurobiological consequences of drug action.
Investigations of the biological effects of abused substances
should likely include the behavioral context of excessive self-
administration, especially if biological treatment approaches are
the goal of such research.
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Receptor Regulation as a
Function of Experience
Fritz A. Henn, Emmeline Edwards, and David Anderson
INTRODUCTION
Seligman and Beagley (1975) demonstrated that exposure to
uncontrollable shock produces a behavioral deficit described as
"learned helplessness." This phenomenon transfers across differ-
ent aversive training and testing contexts; the apparent develop-
ment of an escape deficit seems to depend on factors such as the
nature of the aversive stimulus (Goodkin 1976; Weiss and Glazer
1975), the parameters of the presentation of that stimulus
(Anderson et al. 1976; Rosellini and Seligman 1978), and the
nature of the escape response (Seligman and Beagley 1975; Wilson
and Butcher 1980).
The mechanism by which exposure to uncontrollable shock produces
this behavioral deficit remains undefined. However, we have
established a psychobiological concept of "learned helplessness,"
including a distinct behavioral and neurobiological mechanism
(Henn et al. 1985). Our laboratory has been studying a modified
version of Seligman's "learned helplessness" model in which our
experimental animals are exposed to mild uncontrollable shock
only. With this approach, we have compared two distinct groups of
rats that emerged when subjected to a mild course of uncontrol-
lable shock. The selection was from two different groups of
animals: (1) those that showed no deficit in subsequent shock-
escape tests, and (2) those that showed a profound learning
deficit. This selection has provided a better medium for behav-
ioral and pharmacological manipulations.
ESTABLISHMENT OF A MODEL
Sprague-Dawley rats were used in our experiments. These rats were
obtained from Charles River Breeding Laboratories and were deliv-
ered to the Division of Animal Resources, where they were kept
under standard conditions. Upon arrival, these rats, weighing 150
to 200 gm, were maintained on an ad libitum food and water sched-
ule. Behavioral training and testing sessions were scheduled
during the light phase of a 12-hour light/dark cycle.
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The critical element of our behavioral, biochemical studies is the
consistency and accuracy with which the behavior can be quanti-
fied. There have been numerous reports of a learning deficit that
occurs after exposure to uncontrollable shock; these reports show
only a degree of internal consistency within each investigator's
paradigm. Researchers from various laboratories have agreed that
there is a behavioral difference between response-deficient rats
and rats that have received identical shock but still respond at
control levels (Katz 1981). There is a high degree of variability
in obtaining the behavioral deficit after inescapable shock
training; therefore, in our studies, a revised "learned helpless-
ness" model was used. In our experimental setup, the rats were
placed in an experimental chamber with an electrified grid floor.
Each chamber measured 12 x 18 x 12 cm. Sides and ceilings were
constructed of aluminum and Plexiglas. The floor was constructed
of stainless steel rods spaced 1.9 cm apart. During the shock-
escape test, a level was mounted 7 cm above the grid floor on one
wall. A yellow cue light was placed 5 cm above the lever. Shock
was delivered to each chamber by a Coulborn solid-state shock
source (model E13-16).
SHOCK TRAINING
Training consisted of placing the rats in the experimental cham-
ber, where they received intermittent inescapable 0.8-mA foot-
shock. Each training session lasted 40 minutes. The onset and
offset of the shock being established by a probability generator
resulted in an average schedule of 20 minutes of shock with a
minimum time of 1.5 seconds between on and off events.
SHOCK-ESCAPE TESTING
Twenty-four hours after training, each rat was individually tested
in an escape situation where footshock could be eliminated by a
single bar-press. Shock was delivered at the intensity of 0.8 mA
in a pulsating schedule of 35 msec on/35 msec off, with the yellow
cue light on during the shock period. Shock onset began one
trial; pressing the lever, or the end of 60 seconds, shut off the
shock. Intertrial intervals of 24 seconds began with the yellow
cue light out. Fifteen trials were given in each testing session.
Latencies up to 20 seconds before the lever was pressed and the
shock terminated were considered to be successful escape from
shock. Latencies of 20 to 60 seconds were recorded as failures.
Scores were recorded automatically, with nonspecific effects of
footshock eliminated by including internal controls in the testing
paradigm. Behavioral, pharmacological, and biochemical determina-
tions were carried out for these internal controls. These rats
were subjected only to the shock-escape test, enabling us to
determine the effects of shock per se. Past experiments in our
laboratory demonstrate that these controls routinely do not show
significant changes either behaviorally or biochemically from
measures on nondeficient or naive rats.
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BEHAVIORAL DEFICIT
Behavioral deficits were measured as the number of failures using
the following criteria:
Rats scoring 1 to 5 failures in a 15-trial testing session were
not response deficient (ND) and learned the shock-escape test
as quickly as controls.
Rats scoring 11 to 15 failures in a 15-trial testing session
were considered response deficient (RD).
In a typical experiment, in which a total of 40 rats were used
(10 internal controls; 30 trained and tested in shock paradigm),
30 percent of the trained and tested rats were response deficient
(RD), while another 30 percent were nondeficient and responded at
a level similar to control rats in the shock-escape test. Rats
scoring in the range of 6 to 10 failures were not considered in
subsequent analysis. Behavioral and biochemical determinations
performed on rats falling into the 6-to-10-failures group revealed
a high degree of heterogeneity within the group. In addition, a
large percentage of the 6-to-10-failures group exhibited improved
shock-escape scores when subjected to additional shock treatment
FIGURE 1. Features of escape responding after exposure to
inescapable shock and control responding
NOTE: The figure shows failures to escape In rats trained 24 hours previously.
Dark shading indicates the subpopulation defined as having severe response
deficits (RD), while the lighter shadlng denotes animals having no deficit
(ND) after undergoing identical treatment. The total number of animals
involved was 592, with 27 percent falling in the range of 10 to 15 fall-
ures, and 37 percent between 0 and 4 failures.
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FIGURE 2. Testing of naive rate: Animals exposed to the escape
paradigm with no prior training
NOTE: Sixty percent of these animals scored 0 to 4.
(repeated training sessions). Biochemical determinations, mainly
beta-adrenergic receptor analysis, also revealed a high degree of
variability within the group.
The behavioral deficit exhibited after exposure to uncontrollable
shock was reversed with time. When deficient rats were again
tested in a shock-escape situation, 3 weeks later, their behavior
paralleled the behavior of controls.
We noted that the percentage of rats developing the shock-induced
behavioral deficit was dependent on the strain of rats used.
Routinely, 30 percent of the trained and tested Sprague-Dawley
(SD) rats from Charles River Breeding Laboratories (CRBL) devel-
oped a behavioral deficit in a shock-escape test, while the
Biolabs strain produced only 21 percent of response-deficient (RD)
rats. Rats obtained from Taconic Farms and Simonsen Laboratories
yielded only 11 percent, respectively, response-deficient rats in
the standard training and testing paradigm. This suggested that
the behavioral deficit emerging after exposure to mild, uncontrol-
lable shock may involve a genetic component. Our laboratory has
undertaken the selective breeding of response-deficient (RD) rats,
nondeficient rats, and controls. With data from only three gener-
ations of each group, hereditary differences between our selected
lines are becoming evident. New litters from response-deficient
SD, CRBL rats have produced, under identical conditions of shock
training and testing, 44 percent of escape-response-deficient
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rats. Conversely, litters from nondeficient SD rats have produced
less than 2 percent of animals with a shock-escape deficit. How-
ever, the effect of hereditary differences on behavior must be
characterized thoroughly by biochemical analysis.
NEUROBIOLOGICAL CHANGES
We have identified some neurobiochemical differences between the
two groups emerging after a mild course of uncontrollable shock.
These differences may pinpoint the anatomical locus of the behav-
ioral deficit.
NEUROTRANSMITTERS
Various brain regions were analyzed for their concentrations of
DA, NE, and 5-HT. These neurotransmitter levels were analyzed by
simultaneous assays performed by reverse phase high performance
liquid chromatography (HPLC) with electrochemical detection. HPLC
determinations of the biogenic amines in various brain regions did
not reveal any significant changes in norepinephrine, epinephrfne,
dopamine, or their metabolites in response-deficient rats when
compared to nondeficient rats. However, in the hippocampus, the
serotonin/norepinephrine ratios (5-HT/NE) disclosed some differ-
ences between response-deficient rats, nondeficient rats, and
controls. In general, small, consistent increases in 5-HT and
decreases in NE levels were observed.
RECEPTORS
Beta-adrenergic and serotonin receptors were studied in response-
deficient rats, nondeficient rats, and controls. The various
brain regions analyzed included the cerebellum, hippocampus,
hypothalamus, septum, and anterior neocortex. Major differences
in beta-adrenergic receptors were seen in the hippocampus of
response-deficient rats. The status of beta-adrenergic receptors
(125I-CYP) as the probe. Briefly, hippocampal membrane prepara-
 was assessed by a filtration assay, using 125I-cyanopindolol
tions were incubated  for 55 minutes at 37 °C, with increasing
absence of 10-6M propanolol used for nonspecific binding deter-
concentraions of 125I-CYP (0 to 240 pm) in the presence or
mination (Engel 1981).
In response-deficient rats, the beta-adrenergic receptor was up-
regulated in the hippocampus, but not in the anterior neocortex
nor the septum. Changes in hippocampal beta receptors follow a
time course similar to the shock-escape deficit; a strong correla-
tion between beta-adrenergic receptor status and shock-escape def-
icit scores has been established for the response-deficient rats.
Within 3 weeks following the shock-escape test, both failure
scores and beta-adrenergic receptor status of response-deficient
rats were comparable to controls. Adenylate cyclase responsive-
ness to norepinephrine was determined in response-deficient,
nondeficient, and control rats. Basal and stimulated cyclic AMP
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FIGURE 3. Behavioral and beta-receptor changes with time after
exposure to inescapable shock
NOTE: (A) Rats were trained and tested as described In the text. Cohorts of ani-
mals were subsequently retested at 4, 8, 16, 23, and 42 days. Control
values throughout the experiment remained at approximately 4+2 failures.
(8) Hippocampal beta-receptor measurements were determined using 125I-CYP
as the Iigand and assayed In individual animals according to the method of
Engle (1981). Binding saturation curves were analyzed using an Eadie-
Hofstee transformstion, and BMax was obtained through extrapolation (Zivin
and Wand 1982). Data are expressed as percent of control values. Signifi-
cance was determined using a two-tailed t-test for differences between
means.
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levels were measured using the protein binding assay of Gilman
(1970), in kit form, as provided by Amersham, Inc. Response-
deficient rats exhibited a large increase in adenylate cyclase
activity in hippocampal slices, indicating that an amplification
of the noradrenergic receptor adenylate cyclase system may be
linked to the behavioral changes seen in our model of shock-
induced deficit. Modifications at the receptor level in response
to environmental conditions attest to the plasticity of the
central nervous system and to the involvement of neurochemical
mechanisms in some behavioral responses. In our modified version
of "learned helplessness," there is a biochemical modulation of
the brain in response to a purely environmental manipulation.
This suggests that certain stimuli, obviously drugs among them,
can lead to altered behavioral patterns driven by altered CNS
structures.
PHARMACOLOGY
Pharmacological interventions produced a time-dependent reversal
of both the shock-induced behavioral deficit and the beta-adrener-
gic receptor up-regulation characteristic of response-deficient
rats. In our drug studies, we followed the schedule of training
and testing of our regular paradigm, but shock-escape testing was
followed by a 5-day drug treatment. Tested controls were divided
into two groups, drug treated and vehicle treated. Simultaneously
trained and tested rats were first divided into response-deficient
and nondeficient rats, then each of these two groups were further
divided into a drug-treated group and a vehicle-treated group.
To date, drug studies performed with our model of shock-induced
deficit have focused on compounds known to interact with either
noradrenergic or serotonergic systems. Imipramine (10 mg/kg x 5
days), a relatively nonspecific catecholamine uptake inhibitor,
reversed the behavioral deficit. The shock-escape score of
response-deficient rats improved in 80 percent of the rats re-
tested after the imipramine treatment (11.6±1.8 --> 4.2±3.6
failure scores). A number of tricyclic antidepressants, monoamine
oxidase inhibitors, and second-generation antidepressants were
tested. All clinically effective drugs reversed the learning def-
icit; nonspecific drugs, such as neuroleptics, sedatives, or stim-
ulants, do not appear to reverse the learning deficit. Among the
drugs tested were the relatively specific 5-HT uptake inhibitor
fluvoxamine and the novel compound mianserin, thought to act
mainly through the 5-HT system. Each of these compounds caused
behavior reversal of the deficit.
Interestingly, the reversal of the shock-induced learning deficit
was accompanied by a significant down-regulation of the beta-adre-
nergic receptor in the response-deficient rats. This was expected
for the TCAs such as imipramine , which have previously been shown
to down-regulate beta receptors. It was surprising that the
behavioral changes and down-regulation by betareceptors induced by
imipramine appeared to be similar to, but faster than, the down-
regulation caused by this compound in naive animals. Imipramine
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reversed the behavioral deficit and significantly down-regulated
the hippocampal beta receptors (25 percent down-regulation as
compared to control). Even more unexpected, mianserin lowered the
up-regulation of the beta receptor in response-deficient animals,
while causing no change in the hippocampal beta receptor of non-
deficient rats. Mianserin had previously been shown not to down-
regulate the beta-adrenergic receptors in behaviorally naive rats
(Mishra et al. 1980). Mianserin reversed the behavioral deficit
and significantly down-regulated the hippocampal beta receptors of
response-deficient animals (28 percent down-regulation as compared
to control). Hence the up-regulated receptor seen in our animal
model may be either more sensitive to presynaptic influences or
under the exquisite control of a postsynaptic regulatory process.
So, specific drugs may have an exclusive effect on a pathologic
transmitter system while exhibiting no control over receptors in a
normal or naive animal.
NEUROREGULATORY ROLE OF 5-HT
Studies with mianserin and fluvoxamine suggested that a serotoner-
gic mechanism may also be involved in the mediation of the deficit
produced by mild, uncontrollable shock. The decrease of serotonin
levels prevented the development of the shock-induced behavioral
deficit seen in our model. Sprague-Dawley rats pretreated with
PCPA, a known 5-HT synthesis inhibitor, exhibited shock-escape
scores similar to nondeficient and control rats (3.O±.17 PCPA
treated, vs. 7.6±3.3 saline treated, t=5.96, P<.001).
Bilateral lesions of serotonergic tracts with 5,7-dihydroxy-
tryptamine (5,7-DHT) also prevented the development of shock-
induced behavioral deficit after the training and testing
paradigm. Receptor binding assays or S2 receptors (
3H-spiro-
peridol binding) and S1 receptors (
3H-serotonin binding) in the
anterior neocortex and the hippocampus did not reveal any signif-
icant differences in either the affinity or the maximum number of
sites in response-deficient, nondeficient, or control rats. How-
ever, a normal level of 5-HT activity was necessary to maintain
beta levels in the hippocampus. Recent experiments in our labora-
tories revealed a significant down-regulation of hippocampal beta
receptors after various treatments known to influence 5-HT levels
and 5-HT transmission (BMax in fm/mg protein was 116.5±9.2 in
response-deficient rats, vs. 62.8±5.7 in 5-HT depleted rats).
These studies suggest that a feedback mechanism between noradre-
nergic and serotonin systems could act as a mediator of the behav-
ioral and biochemical characteristics of our response-deficient
rats. Such an hypothesis would support the work of Sulser (1983),
who has suggested that an intact serotonergic input is necessary
for the down-regulation of beta receptors by various therapeutic
drugs.
Our current data do not disclose a simple relationship linking
drug-induced alterations in the 5-HT system, uncontrollable shock,
and behavioral deficits. However, we are focusing our research
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efforts on the following anatomical circuit for our "learned
helplessness" model:
Anterior Neocortex ---> Hippocampus ---> Fornix ---> Septum
GABA NE GABA 5-HT
5-HT
This partial limbic circuit including the hippocampus and the
septum is modulated by neurotransmitter and neurohormonal inputs.
This complex functional "lobe" receives serotonergic, adrenergic,
cholinergic, and peptidergic input in addition to the local
circuitry.
DRUG ABUSE RESEARCH
This work points to the interplay of environmental and genetic
factors in defining the behavioral response to a defined stimulus.
It also shows that the behavioral changes are correlated with the
long-term CNS changes, a correlation that points to the adaptive
plasticity of the CNS. Since addictive behavior appears to share
an interplay between nature and nurture, it may be possible to
utilize animals bred for different responses to drug and alcohol
exposure in isolating anatomic pathways responsive, by addictive
behavior, to these environmental and chemical stimuli. In our
model, successful reversal of the deficit is not produced by stim-
ulants such as amphetamine and cocaine as was found by Sherman et
al. (1979). The role of stimulants merits further testing; the
idea that a particular genetic substrate is required for altered
behavior to occur may be a powerful one for research into drug
abuse. As a start, we would suggest tests of self-administration
under conditions in which there is a wide behavioral response by
animals. The fact that stimulants and hallucinogens have actions
on amine systems also suggests that the circuit activated in our
stress model should be examined under conditions of drug use.
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Clinical and Behavioral
Considerations in Emission
Tomography Study Design
Reese T. Jones
INTRODUCTION
Quantitative imaging of neuroreceptors in the living brain has
only recently passed beyond the "show and tell" demonstration of
feasibility and rather fuzzy, low resolution, computer-generated
images. Much remains to be done, but there is reason for opti-
mism. As chemists become more skilled in synthesizing high spe-
cific activity, high affinity, and positron emitting radioligands.
we can expect experiments with Alzheimer's patients (acetylcholine
receptors), schizophrenics (dopamine receptors), opiate addicts
(the families of opioid receptors), tobacco addicts (nicotine
receptors), etc. Many hitherto untestable models of diseases (at
least untestable in humans), assumed to involve receptor dys-
function, will be put to the test.
A RETURN TO THE STUDY OF HUMAN PHARMACOLOGY
Positron emission tomography studies of neuroreceptors, partic-
ularly quantitative imaging, present a number of challenges to
currently popular research strategies. One major challenge is
that humans are probably the best subject population. Because of
the physics of emission tomography, a large brain is an asset.
Given the resolution of existing and likely instruments in the
near future, rodent brains are too small. Researchers could use
baboons or other large, nonhuman primates; however, the number of
large-brain primates available is relatively small compared with
humans. Even if available, the recording time to accumulate
satisfactory images is so long that the use of unanesthetized or
lightly restrained baboons in the usual emission tomography
setting is not practical. Studies of anesthetized primates are
not the most efficient research strategy if understanding rela-
tionships between receptor function and behavior or cognition is
the goal. Thus, largely because of the technological constraints,
the best research subjects are humans.
The promise of learning about human brain function is the great
advantage and justification for support of expensive, innovative
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technologies. However, most of what we know for sure about recep-
tor function, binding of drugs to receptors, and neurochemistry
comes from rodent tissue cell cultures (often homogenized and
separated) using research strategies and approaches that have not
had to deal with the problems of clinical studies. This chapter
will consider some of the practical problems of dealing with human
research subjects in tomography studies.
Despite justified optimism, proper application of emission tomog-
raphy requires careful thought when posing research questions. It
will be a challenge to design experiments that efficiently confirm
specific hypotheses rather than simply demonstrate that predic-
tions are correct. A host of neurochemical, chemical, biophysi-
cal, and radiologic considerations must be attended to. Other
chapters in this volume (Frost, this volume; Snyder, this volume)
suggest that with time and adequate resources most of these prob-
lems can be managed. Even when procedural and technological
problems are solved, some major constraints will remain for the
design of experiments by those interested in human behavior or
psychology. Limitations on experimental sample size, the special
task demands for research subjects in emission tomography studies,
feasibility of repeated measures, and uncertainty about which sub-
jects may be adequate controls will test the skills of investiga-
tors attempting the early definitive experiments. Although my
focus here is on drug dependence research, many considerations are
general ones relevant to any emission tomography studies of brain
receptor function.
LEVELS OF CHALLENCE DEPEND ON QUESTIONS ASKED
There is a gradation of experiment complexity and demand on the
technology, depending on specific questions. To be most useful,
the imaging of receptors must provide quantitative indices. At
the simplest level, anatomic localization of many types of recep-
tors is obviously feasible; the degree of success will depend
mostly on clever chemists producing a ligand with suitably selec-
tive and specific high-affinity binding and high-activity label-
ling. Physicists and engineers must provide high-resolution
machines. The studies at Johns Hopkins University, described in
other chapters (Frost, this volume; Snyder, this volume), show how
a large group of adequately supported scientists can enable us to
visualize receptor fields in a living brain. However, it is a
long step from the relatively crude anatomic localization of re-
ceptor fields to precise quantitative measures of receptor concen-
tration, distribution, and activity necessary to investigate
mechanisms of disease states.
One limitation in existing technology is the relatively poor
resolving power of currently available imagers, though, at some
installations, resolving power close to the theoretical will soon
be available. For most neurological diseases that are thought to
involve neurotransmitter dysfunction, the variation in neuro-
receptor concentrations seems relatively small. The utility of
emission tomography to quantify small, and probably variable,
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deviations in receptor-field density in small anatomic structures,
for example, the locus coeruleus, must await confirmation. The
precise counting, or otherwise indexing, of numbers of receptors
is a greater task than the semiquantified demonstration of
relatively imprecise anatomic localization evinced so far.
The technology must ultimately provide quantitative indices of
receptor activity, that is, measures of uptake or turnover of
neurotransmitters or other dynamic indices of receptor activity.
Measuring levels of neurotransmitters only, be it in the brain or
elsewhere, tells relatively little about function and can be mis-
leading. The turnover--the dynamics of neurotransmitters--is what
must be determined, which puts a great burden on our still rela-
tively simple kinetic models that relate input and output func-
tions to receptor concentrations. As yet, a complete in vivo
validation of relationships between neurotransmitter uptake or
turnover measures and receptor concentrations is lacking.
Validation in vivo in intact humans may be a formidable task.
MEASURING AMOUNT OF DRUG DELIVERED TO DRAIN
Measuring, even estimating, the actual delivered dose of a
labelled ligand to the brain is not a trivial problem. Dose
deliverance to a specific region of the body or organ is rarely
considered in psychopharmacologic experiments. For example, after
IV administration, before the ligand is available to bind to
receptors in the brain and emit positrons, it first must traverse
the arm, right heart, lung, and left heart before reaching the
brain. All the complexities of peripheral binding, disposition,
and metabolism must be determined before true quantitative indices
of brain measures can be obtained. What is the actual delivered
dose of ligand to brain? The dose , unfortunately, is going to be
different from the dose injected into a forearm vein. For exam-
pie, the dose, or ratio of injected ligand to brain dose, may vary
with different ligands used to selectively label the families of
opiate receptors.
There are, of course, research strategies for measuring organ
dose. Some strategies are purely matters of proper application of
mechanics and plumbing (e.g., carotid artery or lung injections
compared with injections by other routes). The knottier scientif-
ic problem stems from the vicissitudes of quantifying peripheral
drug kinetics, particularly in tissues other than blood. This
quantification can barely be done adequately for the clinical
pharmacology studies that now go on. The proper application of
high technology will force us to deal with the measurement of
far smaller quantitative differences in the face of greater
unaccounted-for variability in drug kinetics.
SLOW MEASURES OF FAST SYSTEMS
The time necessary to accumulate a quantiffable image (currently,
under optimal conditions, about 1 minute; more typically, 15
minutes) places constraints on experimental design and limits
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researchable questions. To a great extent, decreasing image
collection time is a matter of improving the chemistry and physics
of emission tomography. More efficient detection systems and
higher-activity ligands will decrease this time, but there still
will be a relatively narrow time span to work in when trying to
measure dynamic, and probably rapidly changing, neurochemical
events relating to a particular mental state or relating receptor
function to specific behaviors. Most mental states or behaviors
do not hold still for a minute; therefore, the measured receptor
activity may only reflect averaged events.
When attempting to measure a steady state (i.e., more trait-like
mental conditions), the time required for emission tomogram
collection is less of a consideration, and collection can be more
leisurely. But when moving further away from trait-determined
measures into behaviorally or psychologically dynamic states, then
time to accumulate an image becomes a primary consideration for
design of experiments. A previously new and exciting high tech-
nology development from 25 years ago (brain wave-evoked potentials
using an electrical index of brain activity) still has unsolved
problems with this limitation in attempting to measure brain
function correlates of rapidly changing behavioral, psychological,
or subjective states.
HOW RELIABLE ARE THE INDICES?
One tradeoff in using high-activity ligands is the dosimetry
factor, particularly, a more rapid cumulative exposure to radi-
ation. When beginning experiments with any new technology, the
optimal research strategy should include measures of reliability,
whatever the measure. Reliability data will not rapidly accumu-
late since, with current technology, repeated doses of labelled
ligands may, by increments, rapidly exceed recommended radiation
exposure, at least in the case of normal, nondiseased volunteer
research subjects. Of course, when performing a procedure on
someone with an illness and the procedure is to that patient's
benefit, higher radiation doses may be rationalized (assuming it
is a well-designed experiment). Nevertheless, cumulative radi-
ation dose remains a constraint for the near future,
A related consideration that has relevance to the use of high-
affinity ligands and also depends on metabolic considerations is
that adding any drug, maybe even at what are assumed to be,
pharmacologically speaking, "tracer" doses, may perturb the bio-
logical system, particularly as the ligand becomes more potent and
more specific. Traditionally, most perturbations of a biological
system are thought to have a finite time course. It is assumed a
repeated drug challenge will give a similar response some hours,
days, or perhaps weeks later. But what if this new technology
provides the ultimate in sensitivity to small changes in receptor
function? Does that mean that the neuroreceptor correlates of
differences in sensitivity to opiates, as shown by behavioral
indices months or perhaps even a year after a single dose, may now
be evident? This possibility makes repeated-measure experiments a
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little more complicated to interpret, assuming that emission
tomography provides a very sensitive measure.
MERGING NEURORECEPTOR AND PSYCHOLOGICAL MODELS
Other chapters in this volume (Frost, this volume; Snyder, this
volume) discuss neurochemistry, radiologic physics, and a variety
of psychological models and constructs. Implicit in this unusual
mix of topics is a hope or a promise that there should be some
linkage of emission tomography measures of neuroreceptor function
and psychological measures of function, states, and traits (e.g.,
sensation seeking, locus of control, and dependence). Actually
demonstrating such quantitative relationships, no matter how high
the technology, certainly will be akin to finding the Holy Grail.
Optimism should be tempered slightly by noting that, in much
simpler biological models (e.g., rodents or their isolated organs
in Ringer's solution), relationships between receptor-binding
kinetics, receptor function, and psychological function or behav-
for have been modest demonstrations at best and, for the most
part, have not been thoroughly investigated. The question of why
clearly demonstrated and consistent relationships between receptor
kinetics and an organism's function are relatively rare, becomes
relevant when considering the application of an extremely high-
cost, relatively high-risk technology to address questions such as
the relationship between receptor kinetics in one organ system (in
this case, the brain) and behavior or mood. Is it a consequence
of inadequate technology that thus far this has been only tenu-
ously demonstrated when using simpler technologies, or is there a
problem with our models?
WHAT RESEARCH SUBJECTS TO STUDY?
The already complicated list of subject populations appropriate
for the study of drug-dependence-related phenomena becomes more
complicated if one considers the subtypes of drug users described
in Dr. Forgays' chapter (Forgays, this volume). A minimal list of
populations in which one might expect differences in receptor
and/or psychological profiles and functions now includes the
following groups:
Nondrug users ("normal people") who have never used;
Drug users who are not patients in treatment and who:
(1) have no history of treatment,
(2) have a history of failed treatment,
(3) want to stop, or
(4) do not want to stop using drugs;
Former drug users, posttreatment;
Former drug users who are self-determined quitters, who have
never sought treatment.
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This additional level of complexity of user vs. nonuser, treatment
vs. nontreatment subclassifications results from the considera-
tions discussed in Dr. Forgays' chapter. One must assume that
there should be neurochemical/neurotransmitter and psychological
state/trait correlate differences for these subgroups. If not,
why should one, a priori, assume no differences?
Patient selection considerations in studies of the neurochemistry
or neurophysiology of any drug are complex. Given the special
constraints of emission tomography, subject selection becomes even
more important. For example, if a researcher studies current and
regular users of a drug (either the drug of interest or other
drugs), then abstinence syndromes become a potential confounding
problem. When studying opiate receptors, is it best to withhold
tobacco or coffee from the typical tobacco-smoking, coffee-
drinking research subject before the experiment (as is often the
case) for 4, 8, or 12 hours, or is it best to allow regular drug
use? Depending on the researcher's choice, the research subject
is studied in the midst of some ill-defined withdrawal state that
must have neurochemical correlates, or in the midst of an equally
ill-defined drug-induced state, or perhaps somewhere between these
extremes. If a research subject is a regular user of almost any
psychoactive drug, there will be no readily attained, steady, non-
drug state. Given the kinetics of most commonly abused or used
psychoactive drugs, the subject is either entering or leaving a
drug-induced state. A steady (or nondrugged) state in pharmaco-
kinetic/dynamic terms is illusionary in psychopharmacologic
experiments employing people who use psychoactive drugs.
WHO ARE THE CONTROL OR COMPARISON RESEARCH SUBJECTS?
Researchers typically recruit a control sample of some sort of
"nondrug" users. Questions arise such as, who are they? do we
consider caffeine a drug? if we include caffeine users, do they
get their usual caffeine before the experiment, and what are the
implications of caffeine use on adenosine receptors and related
neurochemical consequences? Because there are no clear guide-
lines, to a great extent, the research questions must be
constrained. Much of what we know of neurochemistry has been
generated by studies of inbred, relatively pure genetic strains of
rodents or their even simpler isolated ileum strips or vas
deferens; such experimental preparations do not exist in human
studies. Furthermore, is a completely nondrug-using (no alcohol,
coffee, tobacco, etc.) human control subject a proper control for
many things? I doubt it. If diet to some extent alters neuro-
chemistry, should we control or manipulate that as well?
One solution to the problems deliberately or accidentally posed by
recruiting addicts of one type or another is to create models of
dependent individuals in relatively short-term experiments. This
solution is feasible and, I would argue, not unethical with proper
informed consent. Some preliminary research questions may be
tested with the emission tomography technique by giving opiates,
stimulant drugs, or depressant drugs to nondrug users (or almost
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nondrug users) for a long enough period of time to produce a
sufficient state of dependence.
SAMPLE SIZE
Generally, emission tomography studies that will include large
numbers of subjects in single experiments are unlikely. Large
here refers to large in the statistical data sense. Even though
the cost of an emission tomography experiment will gradually
decrease as technological efficiency is improved, it will still
remain relatively expensive to conduct this procedure for each
test subject. Considering the cost of cyclotron time or other
means of isotope generation, chemical synthesis and cleanup,
personnel, and amortization of rapidly depreciating equipment
(obsolescence is a rapid process in high technology), the total
cost to a granting agency or an institution for each subject
tested in experiments such as those considered in this volume is
in the range of $2,000 per test session. A pilot experiment could
easily cost $10,000 or more to study six subjects.
WILL GOOD MODELS BE PREMATURELY REJECTED OR BAD ONES LINGER?
If a goal is to relate receptor level neurochemical phenomena and
psychological phenomena, particularly concepts such as locus of
control, sensation seeking, or personality variables, studies with
sample sizes of six, or even two or three times that size, are not
likely to be very informative. Good hypotheses and ideas may be
prematurely discarded simply because of tests without adequate
statistical power. Erroneous assumptions of the existence of
relationships resulting from small sample sizes are less of a
problem. False assumptions of the presence of a phenomenon tend
to be disproven with replication. However, possibly good ideas or
good hypotheses relevant to drug dependence, if not confirmed by
the first hundred-thousand-dollar tomography study, may not be
studied again for some years, if ever. The size of samples most
likely to be studied makes impractical the testing of neuro-
psychological relationships that usually appear as 0.3 correla-
tions where only 10 percent of the shared variance is accounted
for.
High technology research studies are not frequently repeated,
since only a relatively limited number of research groups will
have resources to repeat such an experiment and often will not be
inclined to do so. Eventually, when isotope generators become
portable and readily available and when inexpensive emission
tomography transducer rings approach the price of a personal
computer, this situation will change. But even when the hardware
becomes more available, the nature of quantitative receptor imag-
ing is such that the system complexity, the demands on the sub-
jects, and the enormous array of attractive new experiments will
make replication less common than should be the case with a devel-
oping technology. Even poorly posed research questions in this
area of inquiry have such enormous intellectual appeal that it is
unlikely that an investigative group would take time to replicate
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someone else's work rather than proceed with their own "new"
exploratory or, as they might rationalize, more definitive
demonstrations of answers to their own questions.
THE TEST SETTING AND SPECIAL CONSEQUENCES
Currently, and likely for the near future, emission tomography
recording procedures demand relative immobility from research
patients. This need will decrease as technology and chemistry
improve, but it will remain to some degree. Computer processing
of images will improve the situation and correct for some move-
ment, but for ultimate high resolution, relative immobility will
remain a requirement. Thus, many behavioral tasks will be awkward
to run during data collection. Subjects with impaired ability to
cooperate present additional problems.
The mental task assigned to a patient undergoing tomography may be
important. We have learned from emission tomography metabolic
studies that the working areas of the brain have different charac-
teristics, different metabolic patterns, and different blood flow
than relatively quiescent areas. As more sophisticated research
questions are posed, one might assume that this will be true of
receptor function, probably even more so. There probably is no
test condition whereby we can assume that a patient is not per-
forming some mental task or operation. The typical instruction,
"Just relax and don't think about anything," merely gives an
enormous range of options to a patient. The instruction, "Take
the number 938 and successively subtract 7, add 1 to each remain-
der, then give the final value at the end of the experiment,"
assigns a more specific, limited, and operationally defined
task. The experience during quantitative EEG recordings (an ear-
lier high technology development which some researchers thought
would elucidate brain functions) suggests that individual differ-
ences and uncontrolled variance can be reduced by assigning a
task. Almost any task is better than no task. Simply instructing
a person whose head is inside a transducer ring to "lie still and
don't do or think about anything" is a task most humans appear not
to be able to carry out.
A potential problem may arise when assigning tasks. At some
level there should be interactions between psychological con-
structs such as locus of control, sensation seeking, introversion/
extraversion, and neurochemical/receptor function. The demands of
the test situation certainly will alter state, both psychological
and physiological, during the test procedure. Thus, the interac-
tions of trait differences and state effects will need to be kept
in mind when using a sensitive, high resolution procedure purport-
edly measuring correlates of mental function. When dealing with
linear, monotonic functions, the complexity may be unravelled.
However, when nonmonotonic, nonlinear, inverted U, and other com-
plex mathematical functions describe relationships among receptor
function, psychology, and behavior, clever experiments are
necessary if we are to understand these complex relationships.
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CONCLUSION
The application of high technology to the study of human brain
function does not make the design of proper experiments any
easier. As the sensitivity and specificity of brain function
measures improve, attention must be paid to experimental design
considerations that were previously less important because our
measurement techniques were cruder.
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